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Abstract 
The emergence and spread of drug resistance has complicated the clinical treatment of 
malaria, an infectious disease that caused about one million deaths in Africa annually. 
Chloroquine was the first-line treatment until 2001. Chloroquine resistance was detected 
simultaneously in the late 50’s in all main endemic areas, spreading rapidly to South America 
and Africa. Thus, the use of chloroquine has had been discontinued. Chloroquine resistance 
mainly results from a K to T mutation at position 76 within the chloroquine resistance 
transporter, pfcrt. Pfcrt mutations have been reported to be involved in resistance to other 
quinoline drugs, including quinine. In the case of quinine there are evidences suggesting that 
reduced quinine susceptibility results from multiple mutational changes in genetic factors 
other than pfcrt. By analysis of quinine accumulation in the F1 progeny of HB3 x Dd2 genetic 
cross, previous studies have identified a novel quantitative trait locus on chromosome 7, 
termed B5M12 that synergistically interacts with pfcrt in reducing quinine susceptibility.  
Subsequent analysis of 50 field isolates and lab strains could narrow down the locus to 
two candidate genes, including a putative ubiquitin transferase and RAMA (Rhoptry 
Associated Membrane Antigen).  A Y to F mutation at position 1388 in the putative ubiquitin 
transferase was highly synergistically associated with mutant pfcrt in quinine resistance. The 
linkage analysis showed that Y1388F mutation of the putative ubiquitin transferase was co-
selected with the pfcrt K76T mutation under the pressure of quinine treatment. RAMA was 
subsequently excluded as a candidate gene due to a lost of synergy with mutant pfcrt and the 
evidence that RAMA co-segregated with pfcrt. The identification of the putative ubiquitin 
transferase as a potential marker gene might improve the molecular surveillance of quinine 
resistance in the field. In addition, I also investigated the polymorphisms of pfcrt and pfmdr1 
in the 50 field isolates and lab strains. I could observe an additive effect of the geo-specific 
pfcrt M75E mutation in reduced quinine susceptibility. However, for pfmdr1, none of the 
mutation contributed to alter quinine susceptibility.  
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Zusammenfassung 
Die Entstehung und die Ausbreitung von Medikamentenresistenzen hat die 
Behandlung von Malaria, einer Infektionskrankheit, welche mehr als eine Millionen Tote in 
Afrika verursacht, erschwert. Chloroquin war ab dem Zweiten Weltkrieg das wichtigste 
Medikament bei der Behandlung von Malaria. Allerdings trat in den späten 50iger Jahren 
Chloroquinresistenz in Südostasien auf, welche sich dann schnell nach Südamerika und 
Afrika ausbreitete. Deshalb wurde Chloroquin bald darauf abgesetzt. Chloroquinresistenz 
wird hauptsächlich durch eine Punktmutation von Aminosäure K zu T an Position 76 in dem 
chloroquine resistance transporter, pfcrt, verursacht. Pfcrt-Mutationen beeinflussen auch 
Resistenzen gegen andere Quinolinmedikamente wie zum Beispiel Chinin. Im Falle von 
Chinin gibt es Resultate, welche darauf hindeuten, dass Chininresistenz von mehr Faktoren 
beeinflusst wird als pfcrt. Durch Analyse der Chininakkumulation von den Nachkommen der 
genetischen Kreuzung zwischen HB3 und Dd2 in vorherigen Studien konnte ein neuer 
sogenannter “quantitative trait” Lokus auf Chromosom 7 identifiziert werden, B5M12. Der 
B5M12-Lokus interagiert synergistisch mit pfcrt bei der Reduzierung der 
Chininsuszeptibilität. 
Durch eine nachfolgende Analyse von 50 Feldisolaten und Laborstämmen konnten 
wir den Lokus auf zwei Kandiadatengene eingrenzen: die Ubiquitintransferase und RAMA 
(Rhoptry Associated Membrane Antigen). Eine Y zu F Mutation an Position 1388 in der 
Ubiquitintransferase interagiert synergistisch mit mutiertem pfcrt bei Chininresistenz. 
Zusätzlich wurde unter Quininselektionsdruck durch Kopplungsanalyse die 
Ubiquitintransferase Y1388F mit pfcrt K76T co-selektiert. Im Anschluss daran wurde RAMA 
als Kandidatengen ausgeschlossen, aufgrund eines fehlenden Synergismus zu mutiertem pfcrt 
und des Trends der Zusammenlagerung mit pfcrt. Die Identifizierung einer möglichen 
Ubiquitintransferase könnte die molekulare Kontrolle der Quininresistenz im Feld verbessern. 
Zusätzlich haben wir die Polymorphismen von pfcrt und pfmdr1 in 50 Feldisolaten und 
Laborstämmen untersucht. Wir konnten einen zusätzlichen Effekt der geospezifischen pfcrt 
M75E Mutation auf eine verringerte Quininsuszeptibilität zeigen. Im Fall von pfmdr1 konnte 
für keine der Mutationen ein Einfluss auf die Quininsuszeptibilität gezeigt werde. 
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1 Introduction 
1.1 Malaria overview 
More than 40% of the world’s population is at risk of contracting malaria, a mosquito-
borne infectious disease. There are more than a million clinical cases of this disease, which 
causes 781,000 deaths annually in tropical and subtropical regions. Many of the affected 
geographical regions include much of Sub-Saharan Africa, Southeast Asia, and Latin America 
(WHO, World Malaria Report, 2010). The pathogen responsible for malaria is the protozoan 
parasite, Plasmodium, which has the following taxonomy: phylum Apicomplexa, class 
Sporozoa, order Coccidia, suborder Haemosporidiae, and family Plasmodiae. There are more 
than 100 species of Plasmodium parasites that are able to infect various animals, such as 
birds, reptiles, and numerous mammals. Human cases of malaria are primarily caused by four 
Plasmodium species, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovalae, 
Plasmodium malariae, and Plasmodium knowlesi, which infect humans and its conventional 
host, macaques. P. falciparum is the malaria parasite that causes the majority of infections in 
Africa, and it is responsible for the most severe symptoms and mortality. P. malariae is found 
worldwide, whereas the least common malaria parasite is P. ovalae, which is restricted to 
West Africa. Both P. ovalae and P. malariae are relatively uncommon compared with P. 
falciparum. P. vivax is the geographically most widespread but is rarely fatal (Tuteja, 2007). 
P. vivax and P. ovalae are able to enter resting stages, known as the hypnozoite stage, in the 
liver. Hypnozoites cause a clinical relapse anywhere from months to four years following the 
initial infection (Greenwood, 2005).  
Malaria is transmitted by Anopheles mosquitoes. Female mosquitos take blood meals 
to carry out egg production, and these meals are the link between humans and the mosquito 
hosts in the life cycle of Plasmodium species. The key regulatory factors of malaria 
transmission are temperature and humidity (higher temperatures accelerate parasite growth in 
the mosquito) and whether the Anopheles mosquitoes survive long enough to allow the 
parasite to complete its cycle in the mosquito. In contrast to the human host, the mosquito 
vectors do not suffer noticeably from the presence of the parasites.  
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There are 462 species of Anopheles mosquitoes throughout the world. Approximately 
70 species have been shown to be natural human malaria vectors, and 39 species are the 
dominant transmitters of the majority of human malaria parasites (Hay et al., 2010).  
1.2 Global malaria impact 
Malaria is among the five leading causes of death due to infectious disease worldwide 
(following respiratory infections, HIV/AIDS, diarrhoeal diseases, and tuberculosis) and is the 
second leading cause of death from infectious diseases in Africa, after HIV/AIDS. Every 45 
seconds, a child under 5 years old dies in Sub-Saharan Africa due to a malaria infection, 
accounting for 20 % of all childhood deaths in Africa (WHO, 2010).  
The WHO World Malaria Report 2010 estimated that in 2009, approximately 3.28 
billion people lived in areas that have low malaria transmission rates and that 1.2 billion 
people (one-fifth of world’s population) lived in areas with high transmission rates. There 
were approximately 225 million clinical cases of malaria and 781,000 malaria-related deaths 
in 2009. Currently, malaria endemic regions encompass 106 countries. Eighty-one of these 
countries are focusing on malaria control, while 25 countries are in pre-elimination, 
elimination, or prevention of re-introduction phases. Morocco, the United Arab Emirates, and 
Turkmenistan have recently been certified as malaria-free countries. Figure 1.1 depicts the 
countries at risk of malaria transmission in 2010 (WHO, 2010).  
 
      Figure 1.1 Countries or areas at risk of malaria transmission, 2010 
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People living in areas with high malaria transmission rates develop partial immunity 
to malaria within 10 to 15 years. However, during pregnancy, there is a transient depression 
of cell-mediated immunity that not only allows foetal allograft retention but also interferes 
with resistance to various infectious diseases (Uneke, 2007). In areas with high malaria 
transmission rates, women gain a level of immunity to malaria that becomes weaker during 
pregnancy. Malaria infection is more likely to contribute to maternal anaemia and delivery of 
low birth-weight infants (<2500 g or <5.5 pounds). Malaria is particularly problematic for 
women in their first and second pregnancies, for younger women, and for women who are 
HIV-positive. In areas with low malaria transmission rates, women generally do not develop 
immunity to malaria and are therefore more vulnerable to Plasmodium infection during 
pregnancy (Umbers et al., 2011). In 2009, 125 million pregnant women were at high risk of 
malaria infection, which resulted in approximately 200,000 infant deaths (Hviid et al., 2010).   
In addition to mortality and morbidity, malaria is also commonly associated with 
poverty. It is indeed a cause of poverty and a major hindrance to economic development, 
especially in tropical endemic areas. People living in malaria endemic regions cannot afford 
prevention strategies or treatments against malaria. The economic impact of malaria has been 
estimated to be as high as $12 billion USD annually, and a reduction in annual economic 
growth was estimated at 1.3% (Greenwood, 2005). These economic impacts include the cost 
of health care, working days lost due to sickness, days lost in education, decreased 
productivity due to brain damage from cerebral malaria, and a loss of investments and tourism 
(Greenwood, 2005). In some countries with a heavy malaria burden, the disease may account 
for as much as 40% of public health expenditure, 30–50% of inpatient admissions, and 50% 
of outpatient visits (WHO, 2009). In addition, malaria jeopardises demographic transitions in 
Africa by causing high child mortality and infant mortality.  
The cognitive abilities and school performances of malaria-infected children have 
been conclusively demonstrated to be impaired compared to those of healthy children. 
Comparisons of cognitive functions prior to and following treatment for acute malarial illness 
have shown significantly impaired school performances and cognitive abilities even following 
recovery. Malaria prophylaxis has been shown to improve cognitive function and school 
performance during clinical trials compared to placebo groups (Fernando et al., 2010). 
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1.3 Life cycle of Plasmodium species 
The life cycle of malaria parasites is complex and involves two different hosts, the 
invertebrate Anopheles mosquito and another animal, for example a human. Malaria parasites 
in humans develop asexually in two phases, an exoerythrocytic (hepatic) and an 
intraerythrocytic phase. In Anopheles mosquitoes, the parasites undergo a transition from a 
sexual stage to an asexual stage. Figure 1.3 briefly depicts the life cycle of human malaria 
parasites. 
During a single blood meal by Anopheles mosquitoes, thousands of sporozoites are 
released from the salivary gland of the mosquito. Sporozoites migrate rapidly through the 
human skin and into the bloodstream (Amino et al., 2006). Sporozoites subsequently migrate 
to the liver where they adhere to the endothelium of the sinusoid via receptors on the 
sporozoite surface, referred to as circumsporozoite proteins. The sporozoites then enter the 
liver by breaching the Kupffer cells and several hepatocytes before encountering a final 
hepatocyte host. (Frevert and Nardin, 2005; Mota et al., 2001). Subsequently, the entry of the 
sporozoite coincides with the formation of the parasitophorous vacuole, which originates 
from the hepatocyte plasma membrane. Within the hepatocytes, the sporozoites either remain 
dormant hypnozoites, which is only observed in Plasmodium vivax and Plasmodium ovalae, 
or they begin to divide via asexual replication into thousands of merozoites. The parasites 
then induce the detachment of the infected hepatocyte to migrate to the liver sinusoid. The 
parasite-filled merosomes then bud off from the hepatocyte, releasing approximately 10,000 
to 30,000 merozoites into the blood stream. The length of the liver stage varies with 
Plasmodium species: 8-25 days for P. falciparum, 8-27 days for P. vivax, 9-17 days for P. 
ovalae, and 15-30 days for P. malariae (Tuteja, 2007).  
The merozoites that are released into the blood stream evade the human immune 
system by invading and residing within erythrocytes. The invasion process is complicated and 
involves several phases; initial recognition and reversible attachment to the erythrocyte 
membrane; reorientation and formation of the junctions between the apical end of the 
merozoite (irreversible attachment); the release of the contents from the rhoptry and 
microneme; 
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Figure 1.2 The life cycle of human malaria parasites (López et al., 2010). 
formation of the parasitophorous vacuole; movement of the junction and invagination of the 
erythrocyte membrane surrounding the merozoite (accompanied by removal of the merozoite 
surface coat); and resealing of the parasitophorous vacuole and erythrocyte membranes 
following the completion of invasion (Miller and Greenwood, 2002).   The merozoites rapidly 
invade the erythrocytes and replicate, causing the malarial symptoms of a fever and chill 
cycle.  
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During the blood stage, merozoites differentiate into trophozoites. The early 
trophozoite stage is also referred to as the ring stage due to the morphology of the parasite. 
The ring stage parasites substantially enlarge, an event that is accompanied by a highly active 
parasite metabolism, including the glycolysis of large amounts of imported glucose, the 
ingestion of erythrocyte cytoplasm, and the proteolysis of haemoglobin into its constituent 
amino acids. The mature trophozoites again undergo multiple rounds of nuclear division 
without cytokinesis, forming schizonts. Each mature schizont consists of approximately 20 
merozoites, which are released following the bursting of the erythrocyte membrane. These 
merozoites subsequently invade uninfected erythrocytes. The erythrocytic cycle lasts 
approximately 48 hours in P. falciparum, P. ovalae, and P. vivax and 72 hours in P. malariae. 
Similar to the liver stage, the release of the merozoites coincides with a sharp increase in body 
temperature. 
During the erythrocytic stage, some parasites transition into sexual stages, at which 
point they are referred to as gametocytes. Gametocytes are large single-nucleated parasites 
that fill the infected erythrocytes. Once the gametocytes enter the mosquito during a blood 
meal, they develop rapidly into mature male and female gametes and escape from the 
erythrocytes to fuse into a zygote, transitioning into the short-lived diploid ookinete stage. 
The motile and banana-shaped ookinetes migrate across the peritrophic matrix to the midgut 
of the mosquitoes, where they undergo multiple rounds of meiosis, forming an oocyst in the 
basal side of the midgut. Following multiple rounds of asexual replication, mature oocysts 
rupture and release large amounts of sporozoites into the haemocoel. From here, the 
sporozoites flow through the haemolymph and invade the salivary gland, waiting for the next 
bite to begin a new life cycle (Ersmark et al., 2006; Whitten et al., 2006).  
1.4 Clinical manifestations 
Malaria infection results in a broad variety of outcomes, including the absence of 
symptoms, mild to severe symptoms, and even death. Malaria can be categorised as 
uncomplicated or severe (complicated). All of the clinical symptoms are caused during the 
erythrocytic stage. While the parasites reside in the erythrocytes, numerous known and 
unknown waste substances, such as haemozoin pigments and other toxic factors, accumulate 
in the infected erythrocyte. These toxic compounds enter the blood stream following the burst 
of the infected erythrocyte and the release of invasive merozoites. These haemozoin pigments 
and other toxic factors, such as glucose phosphate isomerase, stimulate macrophage and other 
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immune cells to produce cytokines and other factors, resulting in fever, rigors, and likely the 
other severe pathophysiologies associated with malaria (Tuteja, 2007). 
The period between the infective bite by the Anopheles mosquito and the presence of 
the first symptom is referred to as the incubation period. The incubation period of malaria 
varies with the parasite species: 7 days for P. falciparum, and up to 30 days for P. malariae. 
However, when diagnosed sufficiently early and treated correctly, malaria is generally curable.  
1.4.1 Uncomplicated malaria 
The classical malaria symptoms in uncomplicated cases last 6 to 10 hours, including a 
cold stage (a sensation of cold and shivering), which is followed by a hot stage (fever, 
headache, vomiting, and seizures in young children), and finally a sweating stage (sweating, 
normal temperature, and tiredness).  Normally, the symptoms occur every second day with 
tertian parasites (P. falciparum, P. vivax, and P. ovalae) and every third day with the quartan 
parasite P. malariae. However, the egress of P. falciparum is often unsynchronised, resulting 
in a persistent spiking fever or daily fibril paroxysms (Rasti et al., 2004).  
In addition to the above symptoms, patients may also present mild jaundice, increased 
respiration, perspiration, and an enlarged spleen and/or liver on physical examination (Tuteja, 
2007; Miller and Greenwood, 2002). 
1.4.2 Severe malaria  
Severe malaria occurs when infections become complicated by serious organ failures 
or abnormalities in the patient's blood or metabolism. Severe malaria can include the 
following manifestations: abnormal behaviour, impaired consciousness, seizures, coma, or 
other neurological defects in cases of cerebral malaria; severe anaemia and haemoglobinuria 
due to haemolysis; and acute respiratory distress syndrome due to an inflammatory reaction in 
the lungs, inhibiting oxygen exchange and potentially occurring even after the parasite load 
has decreased in response to treatment. Other symptoms of severe malaria can include 
abnormalities in blood coagulation, low blood pressure, acute kidney failure, 
hyperparasitaemia (more than 5 %), metabolic acidosis, and hypoglycaemia, which also 
occurs in pregnant women with uncomplicated malaria or following quinine treatment 
(Miller, 2002). 
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1.5 Antimalarial compounds 
Prescribing malaria treatment needs to be performed carefully with respect to the 
symptom severity, the species of malaria parasite, and the geographic location where the 
infection was acquired. The latter two factors aid in the determination of the probability that 
the parasite is resistant to certain antimalarial drugs. Other factors, such as the age, weight, 
and pregnancy status of the patient, may limit malaria treatment options. 
A suitable antimalarial drug should be well-tolerated, safe, affordable and readily 
available in the endemic areas and have a short regimen. The most common antimalarial 
drugs, their targets, and their target life stages are listed in Table 1.1 (Kappe et al., 2010).  
Table 1.1 Drugs and possible drug targets for drugs targeting erythrocytic-stage and 
liver-stage parasites. ES, Erythrocytic stage; LS, liver stage; DHFR, dihydrofolate reductase; 
DHPS, dihydropteroate synthase; SHMT, serine hydroxymethyltransferase (Kappe et al., 
2010).  
 
Humans depend on the dietary intake of pre-formed dihydrofolate as an essential 
nutrient. Dihydrofolate is reduced to tetrahydrofolate, which is used in the biosynthesis of 
thymine, purine nucleotides, and several amino acids, such as methionine, glycine, serine, 
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glutamate, and histidine. However, malaria parasites can synthesise dihydrofolate from simple 
precursors and use exogenous dihydrofolate via a salvage pathway (Schlitzer, 2009). 
Antifolate compounds, such as pyrimethamine and sulfadoxine (Table 1.1), have been applied 
as an important antimalarial combination (also know as Fansidar) (Wiesner et al., 2003), 
though the rapid emergence of resistance has greatly reduced the efficacy of this drug 
(Yuthavong et al., 2006). Pyrimethamine and sulfadoxine show synergism against P. 
falciparum. The targets of pyrimethamine and sulfadoxine are dihydrofolate reductase 
(DHFR), the crystal structure of which has been determined (Yuvaniyama et al., 2003), and 
dihydropteroate synthase (DHPS), respectively. DHPS does not exist in humans, whereas 
plasmodial DHFR is structurally different from human DHFR. Thus, both enzymes are ideal 
for drug development. DHFR inhibition results in a reduction in tetrahydrofolate levels, 
decreasing glycine to serine conversion, methionine conversion, and lowering thymidylate 
levels. These events in turn arrest DNA replication (Gregson and Plowe, 2005).  
Since the emergence of resistance to quinoline (see section 1.6) and the majority of 
antifolate drugs, artemisinin and its derivatives (artesunate, artemether, and 
dihydroartemisinin) have become important in malaria treatment. Artemisinin is an active 
ingredient from the qing hao weed (Artemisia annua), which has been used as a traditional 
Chinese medicine for hundreds of years to treat fever and several malaria symptoms (Shapiro 
et al., 2005). Artemisinin was first extracted and crystallised in 1971 (Woodrow and Krishna, 
2006). Since then, semi-synthetic artemisinin derivatives with improved potency and 
bioavailabilities have been developed. Two hypothetical mechanisms of action of artemisinins 
in killing erythrocytic parasites have been reported (Eastman and Fidock, 2009; Schlitzer, 
2009; Chaturvedi et al., 2010). First, artemisinins have a unique trioxane structure with an 
endoperoxide bond that is cleaved by reduced haem iron within the acidic digestive vacuole. 
The cleavage of artemisinin forms a free carbon radical, which is able to alkylate specific 
parasitic enzymes and inhibit the haem detoxification pathway, eventually killing the parasite. 
Secondly, the cleavage of artemisinin occurs in the cytoplasm of the parasite and is catalysed 
by a cytoplasmic Fe2+ source. The free radical acts specifically on PfATP6, which is related to 
the mammalian SERCA (sarcoplasmic endoplasmic reticulum calcium ATPase). 
Artemisinins have the shortest half-life among all antimalarial drugs, approximately 
0.5-1.4 hours. Among anti-malaria compounds, it is therefore the least likely that parasites 
will develop resistance against these drugs. However, the widespread monotherapy of 
artemisinins in Southeast Asia has reduced their efficacy and led to a delayed clearance of 
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parasites, especially on the Thai-Cambodia border (Dondorp et al., 2010). To prolong the 
efficacy of artemisinins, they are ideally administrated in combination with at least one other 
antimalarial drug, a practice known as artemisinin-based combination therapy (ACT) 
(Eastman and Fidock, 2009). The WHO has recommended ACTs as the first-line treatment 
for uncomplicated P. falciparum malaria since 2001. However, recent studies have reported 
the possible development of resistance to ACTs (WHO, 2010).  
Several antibiotics known to be active against bacteria are also known to be effective 
against malaria parasites. These antibiotics interfere with the “bacteria-like” DNA replication, 
transcription, and translation in the parasite mitochondria and apicoplast. The mitochondrial 
genome is approximately 6 kb in length and encodes three proteins. However, in parasite 
mitochondria, many components required for translation must be imported from the cytosol. 
The apicoplast genome is approximately 35 kb in length and includes housekeeping genes 
involved in metabolic pathways. Antibiotics such as rifampicin are thought to block RNA 
synthesis in the apicoplast by inhibiting RNA polymerase; whereas tetracyclin, macrolides, 
and lincosamides are thought to inhibit protein synthesis in the apicoplast (Table 1.1) 
(Wiesner et al., 2003; Schlitzer, 2009). 
1.6 Quinine 
The first chemically synthesised and most commonly employed drugs for malaria 
treatment belong to quinine derivatives within the quinoline group. All of the quinine 
derivatives appear to interfere with haem sequestration. Despite the emergence of widespread 
drug resistance to certain quinoline antimalarial drugs, haem is still a viable target for novel 
antimalarial drug development (Wellems et al., 2009).  
1.6.1 History—quinine, quinidine and chloroquine 
The bark of Cinchona officinalis has been used to cure shivering by the Quechua 
Indians in Peru for centuries. The Quechua mixed the ground cinchona bark with sweetened 
water to cover the bitter taste of quinine. During the 17th century, malaria was endemic to 
Rome, resulting in numerous deaths of Roman popes and citizens. In 1640, the Jesuit brother 
Agostino Salumbrino, who received medical training in Lima, introduced cinchona bark to 
Europe to treat the shivering caused by malaria. Thus, cinchona bark was known as Jesuit's 
bark or Peruvian bark and became one of the most valuable goods shipped from Peru to 
Europe (Okombo et al., 2011). Prior to 1820, cinchona bark was first dried, ground to a fine 
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powder and mixed into wine for treatment. Beginning in 1850, people began to use cinchona 
bark as prophylaxis. 
In 1820, the active compound (quinine) of cinchona bark was first isolated by Pelletier 
and Caventou, making malaria one of the first diseases treated with a pure substance (Wiesner 
et al., 2003). From 1860 to 1866, quinine and three other cinchona alkaloids (quinidine, 
cinchonine, and cinchonidine) were evaluated, which was one of the earliest clinical trials. 
The treatment of 3,600 patients indicated that all four compounds are comparable, with cure 
rates of over 98% (Achan et al., 2011). After 1890, quinine became the predominant 
antimalarial drug due to the massive Dutch and British plantations in Java (Indonesia), which 
produced approximately 22 million pounds of cinchona bark (97% of the world’s quinine 
production).   
In 1934, Andersag and his colleagues at Bayer Laboratory synthesised a novel 4-
aminoquinoline compound N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine, 
referred to as Resochin. The Germans ignored Resochin for a decade because it was 
considered too toxic for human use. During World War II, the allied powers were cut off from 
their supply of quinine because the Germans conquered the Netherlands and the Japanese 
controlled the Philippines and Indonesia. However, the United States had obtained four 
million cinchona seeds and planted them in Costa Rica. However, the planting of the 
cinchona tree was too late. Tens of thousands of U.S. soldiers in Africa and Southeast Asia 
died due to a lack of quinine. Thus, the U.S. government conducted clinical trials of other 
antimalarial drugs and unequivocally demonstrated that Resochin had significant therapeutic 
value. In 1947, Resochin, renamed chloroquine, was introduced for prophylaxis and routine 
treatment against malaria in all malaria endemic areas. 
1.6.2 Haemoglobin metabolism and quinine and chloroquine mode of 
action 
During the erythrocytic stage, malaria parasites ingest host haemoglobin via 
pinocytosis to meet their nutrient requirement and to counteract the osmotic imbalance caused 
by their own growth within the erythrocyte (Lew et al., 2004). The mechanism of 
haemoglobin transport into the digestive vacuole is unclear. Lazarous proposed that 
haemoglobin is transported primarily via cytosomes (Lazarou et al., 2009). However, Elliott 
suggested that haemoglobin transport is based on an internalisation mechanism of the host 
cell cytoplasm, one that is independent of actin polymerisation (Elliott et al., 2008). 
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Regardless of where the haemoglobin is digested, various proteolytic enzymes are involved in 
this degradation process, such as aspartic protease plasmepsin (Plm) I, II, and IV and the 
closely related histoaspartic protease (HAP), cysteine proteases (falcipain-1, -2, -2’, and -3), 
the metalloprotease falcilysin, and dipeptidyl aminopeptidase 1 (DPAP1) (Ersmark et al., 
2006). 
The general haemoglobin metabolism pathway is illustrated in Figure 1.3. The precise 
order of cleavage in haemoglobin metabolism is unclear, especially whether a plasmepsin or 
falcipain catalyses the initial cleavage in the hinge region of the native haemoglobin tetramer 
linkage domain. The first cleavage unravels the protein to expose the regions of subsequent 
cleavages into small peptides. These cleavages are performed by both plasmepsins and 
falcipains. The metalloprotease falcilysin can only cleave small peptides (up to 20 amino 
acids), generating oligopeptides. DPAP1 was observed to cleave dipeptides from 
haemoglobin-derived oligopeptides in the digestive vacuole (Ersmark et al., 2006). 
 
Fig 1.3 Haemoglobin metabolism in Plasmodium falciparum (Ersmark et al., 2006). 
The products generated by the haemoglobin metabolic pathway are small 
oligopeptides and possibly free amino acids that are transported across the digestive vacuole 
membrane into the cytoplasm. However, the non-protein component of haemoglobin, haem 
(ferroprotoporphyrin), is not processed inside of the digestive vacuole. Haem is instead 
autoxidised to haematin (ferriprotoporphyrin), causing oxidative stress to the parasite.  
Haematin can bind to and disrupt cell membranes, damaging cell structures and lysing the 
host erythrocyte. The parasite deals with the toxic haematin by biomineralising this 
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compound into an inert and insoluble crystalline, β-haematin, also known as hemozoin or the 
malaria pigment. The hemozoin crystal is approximately 50-200 nm in length and contains 
approximately 80,000 haematin molecules. The formation of haemozoin is likely mediated by 
neutral lipid bodies (Egan, 2008; Coban et al., 2010; Pisciotta et al., 2007).  
Although quinine has been used as an antimalarial drug for centuries, its mechanism 
of action is still not well understood. It is generally believed that the mechanism of action is 
similar to that of chloroquine, which can inhibit the biomineralisation of haem into 
haemozoin (Fig 1.4) (Petersen et al., 2011).  Chloroquine is a weak base with pKa values of 
8.1 and 10.2. Chloroquine is able to freely diffuse across several membranes as a free base. 
While in the acidic digestive vacuole (pH 4.5-5.2), chloroquine is trapped in its di-protonated 
form (Martin et al., 2009). Accumulated chloroquine binds to haematin, preventing the 
detoxification of haem (Fitch, 2004).   
 
Fig 1.4 Chloroquine mechanism of action (Hladky, 2010). Chloroquine (CQ) diffuses 
through membranes into an acidic digestive vacuole, where CQ is protonated (CQH+) or 
diprotonated (CQH22+). CQ inhibits haemozoin biomineralisation by forming a complex with 
haematin (ferriprotoporphyrin, FP). Hb, Haemoglobin. 
Similar to chloroquine, radiolabelled quinine can arrest growing haemozoin polymers 
in the presence of an inhibitor or plasmepsin I, which is responsible for the initial cleavage of 
haemoglobin (Mungthin et al., 1998). A recent study suggests that quinine forms an 
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intermolecular salt bridge with haem, interrupting the formation of the haematin dimer in the 
digestive vacuole. In addition, quantitative trait loci (QTL) analyses using quinine IC90 values 
and quinine accumulation have shown that quinine and chloroquine share at least one 
inheritable resistance determinant, pfcrt, the Plasmodium falciparum chloroquine resistant 
transporter (Ferdig et al., 2004).  
 
1.6.3 Quinine and chloroquine resistance 
In 1967, the WHO defined “drug resistance” as the ability of a parasite strain to 
survive or multiply despite the administration and absorption of a drug given in doses equal to 
or higher than those generally recommended but within the tolerance of the subject (WHO, 
1967).  Following World War II, chloroquine replaced quinine and was used extensively 
against malaria, resulting in the rapid development of chloroquine resistance. The first 
chloroquine-resistant parasite emerged in the Thai-Cambodian area. Resistance also emerged 
in Columbia 10 years following the introduction of chloroquine. Chloroquine resistance 
spread rapidly within 20 years from Southeast Asia to Africa and to new resistant foci, such 
as Papua New Guinea and the Philippines, in the late 1970s (Mita, 2009). To date, 
chloroquine resistant P. falciparum is predominant in nearly all malaria endemic areas 
(Petersen et al., 2011).  
Due to the widespread use of chloroquine, quinine again began to play a key role in 
malaria treatment, including severe malaria, malaria in pregnancy and uncomplicated malaria 
(combined with other antibiotics). However, resistant P. falciparum has developed in 
Southeast Asia and perhaps in some African countries (clinical evidence not available). In 
addition, the efficacy of quinine remained for several decades in malaria endemic areas, 
which may be a cause of the high resistance of parasites to chloroquine (Okombo et al., 2010; 
2011). Although the mechanisms of action of quinine and chloroquine are similar, quinine is 
still administered to treat malaria caused by chloroquine-resistant parasites, indicating that 
quinine resistance involves more factors than chloroquine resistance, which results from a 
K76T mutation in pfcrt. The putative molecular markers involved in quinine resistance are 
pfcrt, pfmdr1, and pfnhe (Mu et al., 2003; Ferdig et al., 2004).  
Pfcrt was identified by analysing a genetic cross between a chloroquine-sensitive 
strain (HB3) and a chloroquine-resistant strain (Dd2); the resistance-mediating locus mapped 
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to the gene pfcrt (MAL7P1.27) (Su et al., 1999; Fidock et al., 2000). Pfcrt encodes a 45-kDa 
putative transporter, which consists of 10 predicted transmembrane domains and is located on 
the digestive vacuole membrane (Fig. 1.5). Different haplotypes Pfcrt are observed with 
respect to the geographic distribution of a given species. All of the mutations observed in 
chloroquine-resistant strains correspond to five origins of pfcrt mutants. Strains from Asia and 
Africa suggest a fitness cost of these mutations in that their prevalence has decreased 
following the discontinuation of chloroquine administration (Table 1.2) (Hyde, 2005). 
Figure 1.5 Topology and mutations in pfcrt (Valderramos and Fidock, 2006). The 
predicted topology of the 10 transmembrane domains of PfCRT is illustrated, with the 
polymorphic residues marked.  
 
The crystal structure and native function of PfCRT remain unknown. Pfcrt homologs 
have been identified in several Plasmodium species (P. vivax, Plasmodium yoelii, P. 
chabaudi, P. knowlesi, and P. berghei). Other PfCRT-like proteins have also been identified 
in several non-related organisms, such as Arabidopsis thaliana. A K76T mutation in pfcrt has 
been identified as the major determinant of chloroquine resistance through the use of allelic 
exchange experiments (Sidhu et al., 2002; Lakshmanan et al., 2005). The K76T mutation is 
also used as a genetic marker in molecular surveillance in several malaria endemic areas 
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(Petersen et al., 2011). Nonetheless, this mutation not only confers chloroquine resistance but 
also determines the level of susceptibility to other structurally related quinoline drugs, 
including quinine (Johnson et al., 2004; Ferdig et al., 2004). The pfcrt K76T mutation is 
highly associated with reduced chloroquine accumulation within the digestive vacuole in 
resistant strains (Cooper, 2007). However, in the case of quinine, reduced accumulation of 
quinine does not always correlate with increased quinine resistance (Sanchez et al., 2008a, 
2011). The K76T mutation-mediated resistance to both chloroquine and quinine can be 
reversed by verapamil, which is used clinically as a calcium channel blocker, and inhibitors of 
drug efflux pump proteins, such as P-glycoprotein (Bellamy, 1996; Sanchez et al., 2008b). In 
addition to the K76T substitution, mutations affecting amino acids 74 and 75 can also alter 
chloroquine and amodiaquine susceptibility, effects that correspond to the differing 
geographic distributions of the mutant pfcrt alleles (Sá et al., 2009). 
 
Table 1.2 Pfcrt allelic variants identified in P. falciparum field isolates and lab strains. 
Mutated residues are shaded in grey. 
 
The second molecular marker that is often associated with quinine resistance is 
pfmdr1 (Plasmodium falciparum multi drug resistance 1, PFE1150w) on chromosome 5. This 
gene encodes a 162 kDa protein, referred to as PfMDR1 or Pgh-1, which belongs to the P-
glycoprotein (P-gp) transporter of ATP-binding cassette (ABC) family. Similar to PfCRT, 
PfMDR1 is located on the digestive vacuole membrane and consists of two homologous 
dimers with 12 predicted transmembrane domains (Valderramos and Fidock, 2006) (Fig. 1.6). 
In bacteria and tumour cells, P-gp is often associated with verapamil-reversible multiple drug 
resistance given that the protein is capable of exporting several structurally and functionally 
unrelated cytotoxic agents (Borges-Walmsley et al., 2003; Valderramos and Fidock, 2006). In 
P. falciparum, PfMDR1 imports the fluorophore Fluo-4 into the digestive vacuole, indicating 
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that PfMDR1 may act as an active transporter of the digestive vacuole, sequestering cytotoxic 
metabolites and importing drugs (Rohrbach et al., 2006). In the same study, Rohrbach et al. 
demonstrated that quinine competes with pfMDR1-meditated Fluo-4 transport. In addition, 
exogenous expression of PfMDR1 in Xenopus oocytes has indicated that this protein is able to 
transport antimalarial drugs in a selective manner. Wild type PfMDR1 transports quinine and 
chloroquine but not halofantrine, whereas the mutant protein transports halofantrine but not  
Figure 1.6 Topology and mutations in pfmdr1 (Valderramos and Fidock, 2006). 
PfMDR1 consists two homologous dimers, each with six predicted transmembrane domains, 
and a nucleotide-binding pocket (NBD, shown in orange box) (Peel, 2001). Each NBD faces 
the cytoplasm of the parasite and binds to ATP. 
Mutations in five residues (86, 184, 1034, 1042, and 1246) have been reported to be 
involved in altering the parasite’s susceptibility to lumefantrine, artemisinin, quinine, 
mefloquine, halofantrine and chloroquine (Table 1.3) (Petersen et al., 2011). The N1042D 
substitution appears to play a role in quinine resistance (Sidhu et al., 2005). Amplification of 
pfmdr1 is also associated with reduced susceptibility to lumefantrine, artemisinin, quinine, 
mefloquine, and halofantrine, while a reduction in pfmdr1 copy number results in increased 
chloroquine resistance (Barnes et al., 1992; Anderson et al., 2009). In addition to mutations 
Introduction	  
 20 
and copy number polymorphisms, nuclear-receptor-mediated responses to drug exposure may 
be a mechanism of gene regulation in P. falciparum (Johnson, 2008).  
 
Table 1.3 Pfmdr1 allelic variants identified in P. falciparum field isolates and lab strains. 
Mutated residues are shaded in grey. 
 
The third molecular marker implicated in reduced quinine susceptibility is a Na+/ H+ 
exchanger (pfnhe, PF13_0019), which encodes a 226 kDa protein located on the parasite’s 
plasma membrane. This protein has 12 predicted transmembrane domains (Bennett et al., 
2007).  The complete function of PfNHE remains unknown, but it has been speculated that 
PfNHE maintains the parasite’s neutral pH (7.4) (Bosia et al., 1993). However, later studies 
have shown that the neutral pH within the parasite is maintained by a plasma membrane V-
type H+-ATPase (Spillman et al., 2009). An increase in the number of DNNND repeats has 
been proposed to be associated with decreased quinine susceptibility (Henry et al., 2009; 
Okombo et al., 2010; 2011). In field studies, however, the association between pfnhe and 
reduced quinine response has been questioned (Briolant et al., 2011; Andriantsoanirina et al., 
2010). Nevertheless, biochemical analyses have demonstrated that reduced expression of 
PfNHE as a result of a truncated pfcrt promoter results in significantly reduced quinine 
susceptibility in vitro (Nkrumah et al., 2009). 
In addition to pfcrt, pfmdr1 and pfnhe, recent studies have identified a multidrug 
resistance-associated protein (Pfmrp, PFA0590w) as a contributor to drug resistance. Pfmrp 
belongs to the ABC transporter C subfamily, which is known to transport anion-like 
glutathione (GSH), glucoronate, and various drugs. PfMRP is located on the plasma 
membrane and membrane-bound vesicles within the parasites. PfMRP is not essential during 
the erythrocytic stage, but its deletion results in increased susceptibility to chloroquine, 
quinine, artemisinin, piperaquine and primaquine. Deletion of this gene also results in the 
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accumulation of GSH, chloroquine and quinine (Raj et al., 2009). Previous linkage studies 
based on in vitro drug susceptibility assays in field isolates have demonstrated that two point 
mutations (Y191H and A437S) reduce quinine and chloroquine susceptibility (Mu et al., 
2003). However, pfmrp is presumably not the major determinant of antimalarial drug 
resistance, and PfMRP possibly acts with other transporters to efflux drugs and other 
metabolites out of the parasites (Raj et al., 2009). 
Previous studies have identified several putative genetic markers that have been 
proposed to play a role in quinine resistance (Mu et al., 2003; Raj et al., 2009; Ferdig et al., 
2004). Interestingly, all of these molecular markers encode various transporters, indicating 
that quinine resistance is associated with reduced intracellular quinine accumulation. 
Following up on this hypothesis, two former Ph.D. students in our laboratory performed QTL 
analyses on susceptibility to quinine and its stereoisomer quinidine and on the initial and 
steady-state intracellular drug accumulation levels in the F1 progeny of HB3 and Dd2 genetic 
crosses (Mayer, 2009; Nurhasanah, 2009). 
1.7 QTL analyses of quinine and quinidine accumulation 
To determine the mechanism of quinine resistance, former Ph.D. students in our lab 
measured the time-course of quinine and quinidine accumulation in the parental strains Dd2 
(quinine sensitive) and HB3 (quinine sensitive) according to a previously described method 
(Sanchez et al., 2003). Quinine accumulation is given as the ratio of the intracellular to 
extracellular quinine concentration. The Dd2 strain accumulates a low amount of quinine, 
whereas HB3 accumulates approximately twice as much quinine as Dd2. Two time points 
were selected for the following studies: 5 minutes for the initial uptake phase and 20 minutes 
for the saturated uptake phase.  
Subsequently, they measured quinine and quinidine accumulation in the 34 F1 
progeny of the Dd2 x HB3 genetic cross. Variations were observed in the quinine and 
quinidine accumulation levels among the progeny; some progeny accumulate quinine and 
quinidine at a level comparable to the parental strains, whereas others exhibit intermediate or 
higher levels of accumulation. This finding indicates that multiple genetic factors may be 
involved in quinine/quinidine accumulation, which is consistent with previous studies 
indicating that quinine resistance is multifactorial (Mu et al., 2003; Ferdig et al., 2004; Raj et 
al., 2009). 
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Previous QTL analyses of quinine IC90 values in the F1 progeny of Dd2 x HB3 
genetic crosses identified three genetic markers that are associated with reduced quinine 
susceptibility: pfcrt, pfnhe, and pfmdr1 (Ferdig et al., 2004). In our group, former Ph.D. 
students performed QTL analyses of quinine and quinidine accumulation. These analyses 
identified a bifurcated peak on chromosome 7 that is highly associated with quinine and 
quinidine accumulation. The downstream locus contains pfcrt, and the upstream locus is 
termed B5M12 (the central microsatellite marker of the locus). The B5M12 locus was further 
investigated to compare the results with those of the previous analyses of quinine IC90 values 
performed by Ferdig et al. in 2004. It was observed that the logarithmic odd (LOD) score of 
the B5M12 locus is significant for the QTL analyses of quinine IC90 values (p <0.01). 
However, the LOD score of the B5M12 locus was higher in QTL analysis of quinine 
accumulation than for quinine IC90 values, suggesting the QTL analysis of quinine 
accumulation is a more sensitive technique for investigating quinine resistance. With respect 
to quinidine, QTL analyses of both accumulation and IC50 data (provided by Dr. Ferdig) gave 
similar results, i.e., both analyses returned a bifurcated peak including pfcrt and the B5M12 
locus. In addition, QTL analyses of quinine IC90 values revealed a second peak on 
chromosome 13. This peak contained the pfnhe gene and was not observed in the quinine 
accumulation QTL study, indicating that PfNHE may be the drug target or involved in the 
parasite’s clearance mechanism (Mayer, 2009; Nurhasanah, 2009). 
To investigate the contribution of pfcrt and the B5M12 locus to quinine and quinidine 
accumulation, they grouped the quinine and quinidine accumulation and susceptibility values 
of the 34 F1 progeny according to the parasites’ pfcrt and B5M12 haplotypes. No significant 
difference was observed between the progeny that possess both loci inherited from HB3 and 
the progeny possessing either pfcrt or the B5M12 locus inherited from Dd2, indicating that no 
loci alone is able to confer the reduced quinine or quinidine accumulation phenotype. It is 
only when the progeny possess both loci inherited from Dd2 that the parasites have 
significantly reduced quinine and quinidine accumulation, suggesting that these two loci 
interact synergistically in reducing quinine and quinidine accumulation (Mayer, 2009; 
Nurhasanah, 2009). 
When they performed the same grouping using data from quinine and quinidine in 
vitro drug susceptibility analyses (i.e., quinine IC90 values and quinidine IC50 values from 
Ferdig’s group), both loci were observed to be required for reduced accumulation of quinine 
and quinidine; the remaining contribution is conferred by the two loci on chromosome 13. 
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Therefore, the synergy between pfcrt and the B5M12 locus appears to genetically characterise 
the altered quinine and quinidine responsiveness of these strains (Mayer, 2009; Nurhasanah, 
2009).  
Patel et al. recently re-investigated the chloroquine responsiveness in the HB3 and 
Dd2 genetic cross and noted a possible contribution of the B5M12 locus in addition to pfcrt. 
To further elucidate the interaction of pfcrt and the B5M12 locus to chloroquine 
responsiveness, they performed a grouping of three different data sets of chloroquine IC50 
values from HB3 x Dd2 genetic crosses. These data were collected from Patel et al. (2010), 
Sá et al. (2009), and their own study. In addition, they analysed chloroquine accumulation. 
Pfcrt alone, independently of the B5M12 locus, confers significantly decreased chloroquine 
accumulation and reduced chloroquine susceptibility. However, the B5M12 locus only 
appears to act additively with pfcrt in terms of reduced chloroquine susceptibility in the data 
set from Patel et al., but this conclusion was not reached for other datasets. Thus, the 
contribution of B5M12 to chloroquine responsiveness is quite different from its contribution 
to quinine and quinidine responsiveness, where both pfcrt and the B5M12 locus are required 
to confer reduced responsiveness (Mayer, 2009; Nurhasanah, 2009). 
The B5M12 locus is approximately 185 kbp long and contains 40 genes. There are 4 
genes encoding tRNAs were excluded from the following study. Further studies are necessary 
to dissect the properties of the B5M12 locus and to identify novel genetic markers of quinine 
resistance therein. 
It has been shown that reduced PfNHE expression as the result of truncated pfcrt 
promoter results in significantly reduced quinine susceptibility (Nkrumah, 2009). However, 
neither quinine nor quinidine accumulation in PfNHE mutants is significantly reduced when 
compared with wild type, indicating that PfNHE may be a target of quinine and quinidine or 
involved in the process of parasite clearance (Mayer, 2009).  
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1.8 Aim of Study  
The aim of this thesis was to dissect this B5M12 locus and identify gene(s) 
contributing to quinine resistance in P. falciparum. The associations of other polymorphisms 
in known molecular markers with quinine resistance were also investigated. A better 
understanding of the genetic bases of quinine resistance will be able to improve the molecular 
surveillance of quinine resistant parasites in the endemic areas and may help preserve this 
valuable antimalarial drug.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipments 
Analytical scales Sartorius, Göttingen 
Autoclave Tuttnauer Systec 2540, Wettenberg 
Centrifuges    
 Biofuge fresco Heraeus Instruments, Hanau 
 Biofuge pico Heraeus Instruments, Hanau 
 J2-MC Beckman, Krefeld 
 L-60 Ultracentrifuge Beckman, Krefeld 
 Megafuge 1.0 R Heraeus Instruments, Hanau 
 Megafuge 2.0 R Heraeus Instruments, Hanau 
 RC5BPlus Sorvall, Langenselbold 
Computer Software 
 Adobe Photoshop ®5.0  Adobe Systems Inc, USA 
 EndNote 8.0. ISI Research Soft, CA, USA 
 Internet Explorer Microsoft Corporation, USA 
 MS Powerpoint 2011 Microsoft Corporation, USA 
 MS Word 2011 Microsoft Corporation, USA 
 SigmaPlot 11.0 Systat Software Inc. 
            BioEdit 7.08 Ibis bioscience, USA 
PyroMark IdentiFire SW 1.0  QIAGEN® 
Swiss-PdbViewer 4.04 Swiss Institue of Bioinformatics 
DNA-electrophoresis apparatus Biorad, München 
Freezer -80°C, UF85-300S  Heraeus GmbH, Hanau 
Freezers -20°C  Liebherr, Biberach 
Fridges   Liebherr, Biberach 
Gas burner gasprofi 1 micro  WLD-TEC 
Glass capillaries GB100F10  Scientific products GmBH, Germany 
Ice machine AF 30  Scotasman, Milano, Italy 
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Incubator (P. falciparum)  Heraeus GmbH, Hanau 
Incubator (bacteria)  Heraeus GmbH, Hanau 
Liquid nitrogen tank   Air Liquide, Ludwigshafen 
Magnetic stirrer   Heidolph, Schwabach 
Microscopes 
Light optical microscope Zeiss, Jena 
Leica DMII Leica 
Confocal laser-scanning microscope Zeiss, Jena 
Microwave oven  AEG, Nürnberg 
PCR machine 
T gradient Thermocycler Biometra, Göttingen 
GeneAmp PCR system 9700 Applied Biosystems, USA 
pH-Meter pH 537  WTW, Weilheim 
Pipetman Gilson P10, P20, P1000  Abimed, Langenfeld 
Multipipetman  Abimed, Langenfeld 
Pipetus-akku  Hirschman labortechnik, Eberstadt 
pipetus® standard Hirschman labortechnik, Eberstadt 
Power supply: Power Pac 300  Biorad, München 
PyroMark™ Q96 ID  QIAGEN® 
Rotor JA20.1  Beckman instruments, USA 
Rotor SS-34, GS-3, SM24  DuPont Instruments, Bad Homburg 
Spectrometer UVIKON 923  Kontron Instruments 
Sterile work bench Herasafe  Heraeus Instruments, Hanau 
Stopwatch  Roth, Karlsruhe 
Trans-blot® SD Semidry transfer cell Biorad, München 
Tweezers  Dumont, Switzerland 
UV-table UV –Transilluminator  Gibco BRL, Karlsruhe 
VarioMACS, MACS system  Miltenyi Biotec, Bergisch Gladbach 
Vortex Genie 2  Roth, Karlsruhe 
Watherbath Julabo 7A  Julabo Labortechnik, Seelbach  
2.1.2 Disposables 
Aluminium foil  Roth, Karlsruhe 
Amicon Ultra Centrifugal Filter Devices       Millipore Corp., Billerica, USA 
MW 30, 50 ml 
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Centrifuge tubes, Polypropylene 18/95 Greiner Bio-one, Frickenhausen 
Clingfilm Saran  Dow Chemical Company, Schwalbach 
Cuvettes  Saarstedt, Nümbrecht, Germany 
Eppendorf tubes  Saarstedt, Nümbrecht, Germany 
Falcon tubes (15 ml, 50 ml)  Corning incorporation, Bodenheim 
Gloves  Harmann, Heidenheim 
Immersion oil  Zeiss, Jena 
Kimwipes lite 200  Kimberly Clark 
MACS-column CS  Miltenyi Biotec, Bergisch Gladbach 
Parafilm  Americal International CanTM, USA 
PCR softtubes 0.25 ml  Biozym Scientific GmbH 
Petri dishes (10 ml diameter) Greiner Bio-one, Frickenhausen 
Petri-dishes (25 ml diameter)  Greiner Bio-one, Frickenhausen 
Pipette Tipps  Corning Inc, Bodenheim 
Plastic pipettes   Corning Inc. Bodenheim 
(1 ml; 2 ml; 5 ml; 10 ml; 25 ml) 
PVDF Membran 0.45 µm   Millipore Corp., Billerica, USA 
Sterile filters (0.2 and 0.45 µm)  Millipore GmbH, Ashburn 
Stiches 
Sterile filtration devices  Corning incorporation, Bodenheim 
Thermowell PCR tubes  Corning incorporation, Bodenheim 
WhatmanTM 3 mm Paper   Whatman Paper Company 
X-ray film  Kodak  
2.1.3 Chemicals 
The chemicals for the purpose of this study were purchased from the firms Roth, 
Merck, Sigma, Serva, Applichem, and GE Healthcare. These were either ordered directly or 
through the chemicals facility of the University of Heidelberg medical school.  
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2.1.4 Kits 
Gel extraction kit  QIAGEN® 
PCR purification kit  QIAGEN® 
High pure plasmid miniprep Kit Roche, Mannheim 
DNeasy Blood & Tissue Kit  QIAGEN® 
SuperScript® III First-Strand Synthesis  Invitrogen, USA 
SuperMix 
Enhanced Chemiluminescence kit Pierce® , U.S.A.   
pyroMark Gold Q96           QIAGEN® 
2.1.5 Biological Materials 
2.1.5.1 Size markers and loading buffers 
6 x DNA loading buffer    Fermentas, Germany.  
GeneRuler 1 Kb DNA ladder plus  Fermentas, Germany.  
2x Protein loading buffer     
PageRuler Plus  Prestained protein ladder  Fermentas, Germany.  
2.1.5.2 Enzymes 
EuroTaq polymerase  BioCat GmbH, Heidelberg, Germany. 
Phusion Polymerase  Fermentas, Germany.  
Restriction Enzymes   New England Biolabs 
DNase I                       Roche, Mannheim 
Lysozyme           Roche, Mannheim 
2.1.5.3 Plasmid 
pET28a(+) Novagen, Darmstadt 
2.1.5.4 E. coli strain 
BL21(DE3) (Stratagene) 
2.1.5.5 Antibodies 
α-6 x His Mouse monoclonal antibody (1:1000) Novagen, USA 
Ubiquitin transferase polyclonal antibody 
Rabbit α –mouse IgG POD        Dianova, Hamburg 
Goat α-mouse IgG Alexa 488        Dianova, Hamburg 
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2.1.5.6 Animal 
NMRI mouse     Charles River, USA 
2.1.5.7 Parasite strains 
Parasite strains used in this study were obtained from the Malaria Research and 
Reference Reagent Resource Center (MR4), USA. 
3D7      chloroquine sensitive strain 
Dd2      chloroquine resistant strain 
HB3      chloroquine sensitive strain 
7G8      chloroquine resistant strain 
GB4      chloroquine resistant strain 
 
Table 2.1 Field Isolates and their origin.  
The genomic DNA of field isolates was kindly provided by Dr. Mu Jiangbing from NIAID. 
Strain Origin Strain Origin 
1088 Thailand Thai18 Thailand 
CP250 Cambodia CP305 Cambodia 
CP313 Cambodia CP285 Cambodia 
CP297 Cambodia CP252 Cambodia 
Thai2 Thailand CP203 Cambodia 
713 Guinea Bissau PNG9-1 Papua New Guinea 
CP201 Cambodia CP269 Cambodia 
CP238 Cambodia P31 Thailand 
98-18 Thailand DIV14 Brazil 
98-5 Thailand DIV17 Brazil 
ECP Brazil 98-11 Thailand 
PBZ945 Brazil M97 The Gambia 
CP256 Cambodia PBZ357 Brazil 
Thai-19 Thailand FCR3 Thailand 
9021 Ghana PAD Brazil 
99-18 Thailand DIV30 Brazil 
ICS Brazil CP271 Cambodia 
98-17 Thailand K39 Kenya 
IF4/1 Liberia REN Sudan 
102/1 Sudan Camp Malasya 
418 Gambia M24 Kenya 
FAB6 South Africa 92-9 Thailand 
M5 Mali   
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2.1.5.8 Oligonucleotides 
The oligonucleotides (primers) used in this study were ordered from Thermo Electron GmbH 
(Ulm). 
 
Table 2.2 Primers for sequencing the genes located in the B5M12 locus. These primers 
were used for identification of polymorphisms in HB3 and Dd2, and subsequently in field 
isolates. 
Gene Primers Position Sequences (5’ to 3’) 
    MAL7P1.16 FWD_7 224590 CAA GAG CAA CAC AAA TTA TTA AC 
 
REV_7 
 
GCT TAG TAC GGA AAA TAT TCT C 
 
FWD_6 225853 GTA AAC CCT TTT GTG GTT TAT C 
 
REV_6 
 
GAA GTA TTC ATA CTT CTC AAG G  
 
FWD_5 226815 CTG TTT TGT TTA TGA GGA TAA G 
 
REV_5 
 
TGG AAA GGA CCT AAA CTT TTC 
 
FWD_4 227954 GTA CAT GTA GAA AAT ATA AAC C 
 
REV_4 
 
CTA TCC ACA TCT TCA TCA GC 
 
FWD_3 229643 CAT GGG TTA TTA TGG TGT CC 
 
REV_3 
 
CAA TAT TGT GGA ATT TAT CTG TG 
 
FWD_2 231209 CCG ACA ATT CAT TAA GAT ACC 
 
REV_2 
 
CTT TCA ATC GTT TGG CTA GC 
 
FWD_1 232282 GAG CCG TAT AAA TTG TAA GAG 
 
REV_1 
 
GTG ATG TAC ATT AAT CAT AAA TG 
MAL7P1.17 FWD_1 235419 CAC CAG CAC CAC CGA CTC  
 
REV_1 
 
GAA AAG GAG AAG ATC ATA AAT AC 
 
FWD_2 236170 GTA TCT TCA AAT ATA AAA ACA GAA C 
 
REV_2 
 
CTT TTC TTT TTA ATA AGA GTT CTT G 
 
FWD_3 238180 GAG CTT AAT ATT CAT CAG GAT G 
 
REV_3 
 
CCC CTT CAA TTT ATT CGA GTC 
 
FWD_4 239343 CTA TAC TGT ATT TCA AGA TAG TAC 
 
REV_4 
 
CAT GTC TTC TAA ATG TTG TAT ATC 
 
FWD_5 241382 CGG AAG AAC AAA GTA TTT ATA CG 
 
REV_5 
 
CGT TGT TTT GTG TTA TCT TAT TTG  
 
FWD_6 242588 GTA TTC CAT ACA ATA ACA AAT ATG 
 
REV_6 
 
CAG TAA AAT ACG AAT TTA GTG AC 
 
FWD_7 244062 CTT AAT CTT CGG AAG TAA TTA C 
 
REV_7 
 
CTA TGT CTA CTT GAA TCC TTC 
 
FWD_8 245038 GAT AAT TAT GAG CAT ATA CTA AAC 
 
REV_8 
 
CGA ACA TAT GTT CAC TTG TAT C 
PF07_0015 FWD_3 247896 GCA ACA TTC TAG ATT TTG AAT AC 
 
REV_3 
 
CCA CTT TTA TTA AAT CTA ATA TTA C 
 
FWD_2 249086 GAA AAT TCA AAC TTG GAA AAT AAT G 
 
REV_2 
 
CAA CTT ATG TGT ATT ACC ATT ATC 
 
FWD_1 250242 ATG GAA AAC GAT AAA CAA AGT AAC 
 
REV_1 
 
CCT TTG TTA ATT CAA TGG ATC TC 
 
REV_1B 
 
GTA GCA TAC TAA CAA GTT CTT GTC 
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Gene Primers Position Sequences (5’ to 3’) 
    PF07_0016 FWD_1 256724 CGA CAA ACA CAT CGG ACC A 
 
REV_1 
 
CCC TCC TTA GTC CTA AAA AC 
 
FWD_2 257256 GGA CCA TCT TAA AAA TGT ATC A 
 
REV_2 
 
GAT GAC ATC TTA AAG CTG TTA C 
 
REV_2B 
 
CTT GGA ATT CTT CTA TAT CTT CA 
 
FWD_3 257664 GAA TGA GAA ACG TCC CAA GTC 
 
FWD_3B 257935 GTT ATT GAA CCT ACC AAT GC 
 
REV_3 
 
TAT TTT TTT TTC TGT TAT TTT TTT TG 
PF07_0017 FWD_1 261100 GTT TTA CAA ATA CCG ATA AAT ATC 
 
REV_1 
 
CAC ACC ATT AGT ATG TCC ATG 
MAL7P1.18 FWD_3 266090 GAG TAG CAA TAA TAT GAT GAA AG 
 
REV_3 
 
GAA AAG GGT ATG ATC TTC ATC  
 
FWD_2 267055 GTC AGC TCC CAG AAA AAA TAG 
 
REV_2 
 
GAA AAA TCC ACC AAT TTC ATA AC 
 
FWD_1 268208 CAA GAC CTT ATA AAC CTC CTA C 
 
REV_1 
 
CTC TTT ATC TTA TTC GCC CTT C 
MAL7P1.19 FWD_7B 271818 CCA AGT GTG ATG ACT TGT AC 
 
FWD_7 272079 GTA CGG GAA CAT CTG CCC  
 
REV_7 
 
TTA TAT TTT ATG AGT TAA AAA AAA AAA 
 
FWD_6 275163 GTG ATG ATC AAC AGG GAA AAG 
 
REV_6 
 
GTT CCT CTG CGT TAT CCA TC 
 
FWD_5 277376 GTC CAA AGG TGA AAT TAC TTC 
 
REV_5 
 
CCC ATG AAG GTA ATT TTT CAC 
 
FWD_4 279674 GAG GAT GAT GAA TCT GGT AG 
 
REV_4 
 
GAT AAG CAT GAA TTA TTA TGA AC 
 
FWD_3 281268 CCT GAT TCT TCC ATA TTA GAT G 
 
REV_3 
 
GAT TTT CTA TTC CTC GAA TAT AC 
 
FWD_2 282835 GAT TAC CTT GAG ATT AGA AGA G 
 
REV_2 
 
GGT TAT CTC ATC ATT TAT AAA TTC 
 
FWD_1 284139 CAA TTG AAT TTG TCA GCT GAC G 
 
REV_1 
 
CTT CTT CAC TCT CTT CCT CTG  
PF07_0018 FWD_1 288842 CGT ATA CCA GAA GGC AAG GG 
 
REV_1 
 
GTC CCT GCA AAT AGA CCT ATG  
 
FWD_2 289399 CAG ATG AAT GTG TTA AAA GAG G 
 
REV_2 
 
CCA TTA ATT TCT GAG TCC TTA G 
 
FWD_3 290411 CCT AAA AAG AAT TCA CGA CCC 
 
REV_3 
 
GAT TCT TTG TTT TTT CCT TAT CA 
 
FWD_4 291149 CAG TTC ATA ATC GAA AAT CTC T 
 
REV_4 
 
GTA ACG GAG CGA TAC TTT TG 
 
REV_4B 
 
GAA TCA CTA TTT ATA TGA TCA CA 
PF07_0019 FWD_2 296498 CAA ACA TCC AAA CAA ATG TTA TG 
 
REV_2 
 
GGA TTG GGC CAA TTC GGA G 
 
FWD_1 297410 ATG GAG AAG CTT TTA CAC AAA TG 
 
REV_1 
 
GTT GTC ATA TAT TAT GTC ATC CC 
 
REV_1B 
 
CTA CAC ATG TGT GCA TCA CC 
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Gene Primers Position Sequences (5’ to 3’) 
    PF07_0020 FWD_3 302161 CGA TTA CCC TTG AGA ACG AC 
 
REV_3 
 
TTA CAT AGT TCC GAA TAT AGT TG 
 
FWD_2 303912 GCA AGT TTT TGT GTA AAT ACT C 
 
REV_2 
 
GTC ATT ATT ACA TAA GCC TTT C 
 
FWD_1 304878 CCT ATA CTT AAT GAA ACT ATA TTA C 
 
REV_1 
 
CAC TAT CCG CAC ATA CAC TAC 
PF07_0021 FWD_1 307664 GAG TAT TCA TAT CAG TGA TGA AG 
 
REV_1 
 
GAC TAA AAG TAC CTG GGC AAC 
 
FWD_2 308684 CAA TCG TAA GAA TTA TGA TCA AC 
 
REV_2 
 
GTT CAT TTA TGT TTT GGG AAT TC 
PF07_0022 FWD_1 311466 ATG ATG TTT CCT TGT ATA AAT AAC 
 
REV_1 
 
GAT TTA TTG TGT TCA ATG CAT TC 
 
FWD_2 312741 CGC ATG GAA AGG GAT AAG G 
 
REV_2 
 
GTA ACC AAT ATC TTA TCT ATA TG 
 
FWD_3 315100 CGA ATA TAC ACA ACC AAA ATA TG 
 
FWD_3B 315211 CTG ATT ATG ATC AAA TAC AAG AAC 
 
REV_3 
 
GTT TGT TGT GTG TCT AAG GTC 
MAL7P1.21 FWD_1 317485 GTG TTA TTA TAA GAA TCC CCA G 
 
REV_1 
 
GTA TGA TGT AGT TTT CTT CTT TG 
PF07_0024 FWD_5 326973 GAA AGA AGG TAT GAC CCA CC 
 
REV_5 
 
GTT AGT AGT ATA TTT ACT TAT ACC 
 
FWD_4 329566 GGA GAT CAT TCT TAG GTT CTG 
 
REV_4 
 
CTA TCA GAA GTG CTA CTA TCG 
 
FWD_3 331662 CAA GGA TAT ATA TCT TAC ACA TC 
 
REV_3 
 
GTC AAG TAA GTA ATT TTC AGT AG 
 
FWD_2 332958 GTG ACA AGG ATA GCT ATT C 
 
REV_2 
 
GTT CCA CTT CGA CCT CTT C 
 
FWD_1 334066 ATG AAT GCA TAT AAC ACA GAC G 
 
REV_1 
 
GCA TTT ATT GGT ATG ATA TCT AC 
MAL7P1.201 FWD_3C 336630 CAA GAT ATC CTA ATA GAC AAG C 
 
REV_3 
 
TTA AAA GTA AGT TTT CTT CTG ATA T 
 
FWD_2 338772 GAA TAA TCA ATT GAA TAG TTT AAG 
 
REV_2 
 
CTG AAA TAG CAC AGG TTT TAG 
 
FWD_1 339793 ATG AGG AAT CGT TTG TTT TAT G 
 
REV_1 
 
CCT ACC TCT ATA AGA AGT ATC  
MAL7P1.202 FWD_1 348781 ATG CAG AAC CTT TTA AAT ACC AG 
 
REV_1 
 
GAT CAT TTT CAT TAG TAA CAT TAT G 
 
REV_1B 
 
CTA ATA GCG AAA AAT TAT CTG GG 
MAL7P1.203 FWD_3 354302 GAG AAT AGA AAC ATG TAT AAG G 
 
REV_3 
 
TTA CTT TTT TAA AGT GTC CAT ATA 
 
FWD_2 357724 CAT AAG GAT ACC TCT CTT GAG  
 
REV_2 
 
CTA CAC TTT CTT CCA TGT TGG 
 
FWD_1 358416 ATG ATA AAG TAT CGT TTA TTT AAT A 
 
REV_1 
 
GAC CTG CAC TTA CAC AAC C 
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Gene Primers Position Sequences (5’ to 3’) 
    MAL7P1.230a FWD_1 360947 GAA GAA GAA AAA AAT GAA CAA TTC G 
 
REV_1 
 
TCT TTT TAA AAG AAA TTC AGA TAT TTG 
 
FWD_1 362492 GGT AAA GCC GGA AAA GGT AC 
 
REV_1 
 
TCT TTG TTT TGG TTT TGG AGT AC 
 
FWD_1 362495 ATG GGT AAA GCC GGA AAA GG 
 
REV_1 
 
TTA TCT TTG TTT TGG TTT TGG AG 
MAL7P1.204 FWD_3 367098 CTA TAC CAG TGA ATG GAA AAC  
 
REV_3 
 
GAA GAA TTG TTA TTT GCA TTA TG 
 
FWD_2 368079 CAT ATG TAG TAA TGA AAA GAG TG 
 
REV_2 
 
CAT ATA AGC ATC AAA CGG AAT G 
 
FWD_1 370215 CAG TAG AAG GAG AAA ATC ATG 
REV_1  CTT CTG GAT ATA ATT TTC CCG 
MAL7P1.205 FWD_1 375627 ATG AAA ATC ATC CTA AAA AAT GTC 
 
REV_1 
 
GTC ATA CAT TGT GCT AAT GTT G 
MAL7P1.207 FWD_5 385887 CCT GAT AAA AAT TAC AAT TAT AAT G 
 
REV_5 
 
TTA GTT TGG ATT ATT CTT ATT GTC 
 
FWD_4 387922 GAG TAT AAG AAC GTC TTT TCT G 
 
REV_4 
 
CAA GCA TAA AAT TCG ATT CCC C 
 
FWD_3 388803 CAT AAA GGA TAT GTG GAT GCA G 
 
REV_3 
 
CTT TCG AAT CAT TTT ATC TTT TAT C 
 
FWD_2 390071 CTT TAG TAG TGA TAT GTC AAA TTC 
 
REV_2 
 
CAA ATT CAC TGC TAA TAA TTA AAT C 
 
FWD_1 391677 CTT ACC ACT TGT TCA  AAA  AAT TAC  
 
REV_1 
 
CCT CCT GTG GTA AAG GAT C 
 
REV_1B 
 
CTA GAA TTC TCG GCT TCT AAG 
MAL7P1.208 FWD_1 394270 GTT CTA CTT CTG TCT TTG CTT G 
 
REV_1 
 
CAT AAG AAT CAG TTT CTA AAA AGC 
 
FWD_2 395112 GGA ATA CGG AGA GAG TTT CC 
 
REV_2 
 
GTC TTC CAT ATC GTT TTG TTT G 
 
FWD_3 395827 GTC TTT TAT GAT TTA TAC AAG CC 
 
REV_3 
 
TTA ATT CAT AAA ATA TAA AAG GGT G 
MAL7P1.209 FWD_1 399291 ATG AAT TTT CCT AAT TTG AGT AAG 
 
REV_1 
 
GAA TAC CTA ATG CAC TAA CAT C  
 
REV_1B 
 
CAT GTT GAT TAC GTA ACC ATT C 
 
FWD_2 400959 GAC ACC AAA GTT GTT ACA  AAG 
 
REV_2 
 
TCA CAA TTG TTC ATT TAT TAA TAC 
MAL7P1.22 FWD_1 404287 CAA AGA AAA AAA ATA TAC GTG GG 
 
REV_1 
 
CAT TTG ACT TGC CCT TAA AAA C 
 
FWD_2 405476 CGA TAT TAA TAA TAA TAT GAT AGA C 
 
REV_2 
 
CAA TAA CTT TAA TCG ATT TGT CC 
 
FWD_3 406612 CTG TTA GAA CAT ATT TTT GTA ATT G 
 
REV_3 
 
CAA GGT ATT CAT ATC TTC CTT AG 
 
FWD_4 407616 GAA GAT ATA TTA AGT AAA GAA AC 
 
FWD_4B 408097 GTT ATA ATC AAC ACG ATA GTG 
 
REV_4 
 
TTA GTT TGT ACA AAA TTT GTT GT 
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Gene Primers Position Sequences (5’ to 3’) 
    
PF07_0026 FWD_1 413208 GAA CAT GTT GAT GAT AAC AAA AC 
 
REV_1 
 
GAG GAA ACA GAT GAG CCA TC 
 
FWD_2 414430 CAA ATG ATA GTT ATA CAA GAA ATG  
 
REV_2 
 
GAC TGG AAT GAT TTA TAT GGT G 
PF07_0029 FWD_1 438955 GGA TAT GTA TAT GGG AAT GTG C 
  REV_1   GGA ATC GGA GTA ATT CGG TG 
    
    
Table 2.3 Primers for length polymorphism identification. Primers were designed for short 
PCR products (150~450 bp), and analyzed with either 2% Agarose gel or 3% Metaphore gel. 
Name Location  Sequences (5’ to 3’) 
    
SM205 MAL7P1.205 FWD GTT CTC TTA GAC TTT GTT ATC 
  REV GTC TGA TTT ATG GCA TCC TTT 
SM207 MAL7P1.207 FWD GTG GAT GCA GAT CAT TAT TCC 
  REV CAT CTT GTG CAC ACA AAC TTG 
SM208 MAL7P1.208 FWD CAG TTA CCA AAA GGT ATC TAC 
  REV CTA ATT CTT CAG CAG TCA TAG C 
SM22 MAL7P1.22 FWD GTT TAA CGA TAT ATA TAG TAA TGA 
  REV GAA AAT AAA TTT TCT TCT ACA TAC 
SM17 MAL7P1.17 FWD CAG GAT GAA AAC GTA TCT ATT G 
  REV GGT AAT AAA AGA TAA ATC ATT GTG 
SM15 PF07_0015 FWD GTG CTA ATG AAG ATG AGG ACC 
  REV CTA ATT AAG TCG TTA CTC TTT TG 
SM19 PF07_0019 FWD GTC ATC AAA CTG GGA ATT GAA C 
  REV GGA TTG GGC CAA TTC GGA G 
SM20 PF07_0020 FWD CCG TAT GAG CAC TTT TTA GAA 
  REV ACT ATT CAT TTT TTC TCG ACA G 
SM21a PF07_0021 FWD-1 CTA TTT ACA CTT TGA TTA GTT CC 
  REV-1 CCT TTG AAT CTT ATG AAA AAT GAT 
SM21b  FWD-2 CCT TTG AAT CTT ATG AAA AAT GAC 
  REV-2 GAA TGA TTA ATT TCG TAT TCA TCG 
SM22a PF07_0022 FWD-1 GAT TTA TTG TGT TCA ATG CAT TC 
  REV-1 CTG ATT ATG ATC AAA TAC AAG AAC 
SM22b  FWD-2 CTG ATT ATG ATC AAA TAC AAG AAC 
  REV-2 CAT GTA CAA GTT GTA ATA AAA TAC 
SM24a PF07_0024 FWD-1 CAA AGC AAT TCC ATG TTT GAT C 
  REV-1 CCT CTG AAA GTT TAC TAT CAC G 
SM24b  FWD-2 GAA CCT ATA AAA GTG AGC ACG 
  REV-2 CCA TCT CCA TTA TCA TAA CCG 
SM24c  FWD-3 GGA GTT GAT GAG GAT GAC GA 
  REV-3 CTA TCA GAA GTG CTA CTA TCG 
SM22 MAL7P1.22 FWD GGA TAT GTA TAT GGG AAT GTG C 
  REV GGA ATC GGA GTA ATT CGG TG 
SM29 MAL7P1.29 FWD GGA TAT GTA TAT GGG AAT GTG C 
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  REV GGA ATC GGA GTA ATT CGG TG 
Table 2.4 Primers in PfCRT K76T nested PCR (Djimdé et al., 2001). 
PCR Name  Sequences (5’ to 3’) 
    
1st PCR CRTP1 FWD CCG TTA ATA ATA AAT ACA CGC AG 
 CRTP2 REV CGG ATG TTA CAA AAC TAT AGT TAC C 
2nd PCR CRTD1 FWD TGT GCT CAT GTG TTT AAA CTT 
 CRTD2 REV CAA AAC TAT AGT TAC CAA TTT TG 
 
Table 2.6 Primers for pyrosequencing of PfCRT 326 residue polymorphism.  
Name  ssfas Sequences (5’ to 3’) 
    
PfCRT_326 FWD FWD GAT GAT TGT GAC GGA GCA TG 
 REV 5’ biotinylation CTA TTG CTG GAC CTT GTA TAC 
 Pyro Sequencing  CCT TCG CAT TGT TTT CCT TC 
 
 
Table 2.7 Primers for identification of PfMDR1 mutations (Duraisingh et al., 2000). 
Name Sequence (5’ to 3’) Position 
   
A1 TGT TGA AAG ATG GGT AAA GAG CAG AAA GAG -9~21 
A3 TAC TTT CTT ATT ACA TAT GAC ACC ACA AAC A 648~618 
A2 GTC AAA CGT GCA TTT TTT ATT AAT GAC CAT TTA 584~552 
A4 AAA GAT GGT AAC CTC AGT ATC AAA GAA GAG 24~54 
O1 AGA AGA TTA TTT CTG TAA TTT GAT ACA AAA AGC 3003~3035 
O2 ATG ATT CGA TAA ATT CAT CTA TAG CAG CAA 3889~3860 
1034f AGA ATT ATT GTA AAT GCA GCT TTA TGG GGA CTC 3067~3099 
1042r AAT GGA TAA TAT TTC TCA AAT GAT AAC TTA GCA 3299~3267 
1246f ATG ATC ACA TTA TAT TAA AAA ATG ATA TGA CAA AT 3545~3589 
 
2.1.6 Buffers, Media and Solutions 
Cell culture medium     10% Human serum 
0.2 µg/ml Gentamycin 
0.1 mM Hypoxanthine 
in RPMI 25 mM HEPES L-Glutamine (Gibco) 
Freezing Solution     28% Glycerol (v/v) 
3% D-Sorbitol 
0.65% NaCl in ddH2O 
filter sterile, kept at 4ºC 
MACS buffer      1x PBS 
2 mM EDTA 
0.5% BSA 
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Sorbitol Solution     5% (w/v) D-sorbitol in ddH2O filter sterilized 
TAE      40 mM Tris-acetate 
1 mM EDTA 
TE Buffer      10 mM Tris/HCl pH 8.0 
1 mM EDTA 
Thawing solution I     12% NaCl, autoclaved 
Thawing solution II     1.6% NaCl, autoclaved 
Thawing solution III     0.9% NaCl / 0.2% glucose filter sterilized 
Ampicillin stock, 100 x   50 mg/ml in ddH2O 
APS   10% (w/v) APS in ddH2O 
Blocking solution   5% (w/v) skimmed milk in PBS 
Coomassie Destaining solution   5% methanol 
   10% acetic acid 
Coomassie Staining solution   5% methanol 
   10% acetic acid 
   0.0.5% Coomassie Brilliant Blue R-250 
DNA loading buffer, 6 x   9 mg Bromophenol blue 
   9 mg Xylene Cyanol FF 
   Dissolve in 8.8 ml of 60% Glycerol and 
   add 1.2 ml of 0.5 M EDTA 
LB broth   10 g Tryptone 
   5 g yeast extract 
   5 g NaCl 
   Dissolve in 1 l ddH2O and autoclave 
LB agar   10 g Tryptone 
   5 g yeast extract 
   5 g NaCl 
   15 g Agar 
   Dissolve in 1 l ddH2O and autoclave 
RNA gel running buffer, 20 x    20 mM MOPS 
   2 mM Sodium Acetate 
   0.25 mM EDTA 
SDS loading buffer, 2 x    8 M Urea 
      5 % (w/v) SDS 
      40 mM Tris-HCl pH 6.8 
      0.1 mm EDTA 
      0.4 mg/ml Bromophenol blue 
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SDS-PAGE running buffer   25 mM Tris 
   192 mM Glycine 
   0.1% SDS 
Semi-dry transfer buffer   48 mM Tris 
39 mM Glycine 
   0.38% (w/v) SDS 
SOB   20 g Tryptone 
   5 g Yeast extract 
   0.5 g NaCl 
   0.186 g KCl 
   Dissolve in 1 l ddH2O and autoclave 
SOC   SOB with 20 mM Glucose 
TB buffer     10 mM Pipes  
      55 mM MnCl2 
      15 mM CaCl2 
      250 mM KCl 
      Adjust PH to 6.7and autoclave 
Lysis buffers     100 mM NaH2PO4 13.8 g  
10 mM Tris-HCl 1.2 g Tris  
6 M Guanidine HCl 573 g  
   Dissolve in 1 l ddH2O 
Adjust pH to 8.0 using NaOH 
Wash buffer I     100 mM NaH2PO4 13.8 g  
10 mM Tris-HCl 1.2 g Tris  
8 M Urea 480.5g  
   Dissolve in 1 l ddH2O 
Adjust pH to 6.3 using HCl 
Wash buffer II     100 mM NaH2PO4 13.8 g  
10 mM Tris-HCl 1.2 g Tris  
8 M Urea 480.5g  
   Dissolve in 1 l ddH2O 
Adjust pH to 5.9 using HCl 
Elution buffer      100 mM NaH2PO4 13.8 g  
10 mM Tris-HCl 1.2 g Tris  
8 M Urea 480.5g  
   Dissolve in 1 l ddH2O 
Adjust pH to 4.5 using HCl 
Erythrocyte lysis buffer   50 mM NH4Cl 
      2 mM EDTA 
      5 mM Hepes, pH7.4 
      1 mM PMSF 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 In vitro culture of Plasmodium falciparum 
P. falciparum lab strains (Dd2, HB3, 3D7, 7G8, and GB4) in erythrocytic stage 
provided by MR4 were maintained in continuous blood culture as previously described 
(Trager and Jensen, 1976). Briefly, the parasites were cultured in in either 10 cm or 25 cm 
petri dishes with A+ human erythrocytes of approximately 5% hematocrit containing 15 ml or 
35 ml HEPES buffered RPMI medium, respectively, supplemented with 10% heat inactivated 
A+ human serum, 200 µM hypoxanthine and 20 µg/ml gentamycin. Parasites were incubated 
at 37°C in an atmosphere of 3% CO2, 5 % O2, 92 % N2, and 95% humidity. The medium was 
changed everyday and the parasitemia was determined by Giemsa staining. On reaching 
parasitemia of 5-10%, the cultures were passaged to avoid parasite death due to lack of 
nutrients or accumulation of toxic metabolites in the culture medium. 
2.2.1.2 A+ human serum and A+ erythrocytes preparation 
All materials used in the parasite cultures were provided by the German Red Cross 
blood bank, Heidelberg. A+ human serum was aliquoted in 50 ml falcon tubes. 800 µl of 
sterile 1 M CaCl2 was added to each aliquot, incubated at 37ºC for 30 minutes and then at 4ºC 
overnight. The aliquots were centrifuged (4000 rpm, 30 minutes) on the following day to 
pellet the fibrin, and then inactivated at 56ºC for 30 minutes. The aliquoted serum was stored 
at -20ºC. A+ erythrocytes were also aliquoted in 50 ml falcon tubes, suspended in 10 ml of 
RPMI medium. The aliquots were centrifuged (2300 rpm, 4 minutes without break) and 
stored at 4ºC. 
2.2.1.3 Giemsa staining and parasitemia determination 
50 µl of the parasite culture was spread as a thin smear on the surface of a clean 
microscope slide, air dried, fixed in 100% methanol for 30 seconds, and air dried again. Fixed 
smears were stained in 10% Giemsa solution for 10~15 minutes, rinsed with water and dried. 
Slides were examined on a light microscope using a 100 x objective under oil immersion. 
Parasitemia was defined as the percentage of P. falciparum infected erythrocytes. The 
numbers of both infected and total erythrocytes were counted in 10 consecutive fields and 
parasitemia was the calculated according to the formula: (Number of infected erythrocytes/ 
Number of total erythrocytes) x 100 = parasitemia in %.  
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2.2.1.4 Parasite synchronization with Sorbitol 
Sorbitol causes osmotic lysis of late stage trophozoites (Lambros and Vanderberg, 
1979) due to the presence of an induced transport pathway in the infected erythrocyte 
membrane, which is permeable to sorbitol and absent during the ring stage. To synchronize 
parasite cultures, the culture medium was removed from the plate; following with the cells 
were suspended in 10 ml of 37ºC pre-warmed 5% D-Sorbitol solution and transferred to a 15 
ml falcon tube. The tube was then incubated for 10 minutes at 37ºC, followed by 
centrifugation for 2 minutes at 1900 rpm at room temperature. The pellet was then transferred 
back to normal culture condition (2.2.1.1).  
2.2.1.5 Parasite freeze-thaw 
The percentage of ring stage parasites affects the speed of parasite survival after 
thawing, so a culture containing at least 5% rings is suggested for freezing. This was done by 
removing most of the culture medium, resuspending the cells in the residual medium, and 
subsequently centrifuge for 2 minutes at 1900 rpm. After discarding the supernatant, the pellet 
was resuspended in equal volumes of sterile freezing solution and mixed gently. The mixture 
was then aliquoted into two 2 ml cryotubes and snap frozen in ethanol/dry ice slurry for 15 
minutes before transferring to a -80ºC freezer. For long-term storage, cryotubes were stored at 
-196ºC in a liquid nitrogen tank. 
To thaw the parasites, the cryotubes were warmed for 2 minutes in a 37ºC water bath 
immediately after they were taken out from the -80ºC freezer or liquid nitrogen tank. The tube 
was then transferred the culture to a 15 ml falcon tube and followed by addition of 200 µl of 
thawing solution I with a speed of 2 drops per second, and mixed gently. Then 9 ml of 
thawing solution II was added drop wise and centrifuge at 1900 rpm for 2 minutes. The 
supernatant was discarded and 7 ml of thawing solution III was added drop wise, followed by 
centrifugation with the same condition. The pellet was then transferred back to normal culture 
conditions (2.2.1.1). The culture was kept in the incubator for at least two days to allow the 
parasites to revive. All solutions used in freeze thawing were pre-warmed at 37ºC. 
2.2.1.6 Parasite purification with MACS 
To obtain high purity of trophozoites (95 to 97%) for immunofluorescence or Western 
blot assays, trophozoite-stage cultures of parasitemia ≥ 5% were passed through a magnetic 
column before the experiment. This technique takes advantage of the paramagnetic property 
of hemozoin within the parasites, compared to the diamagnetic oxyhemoglobin in the 
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erythrocytes (Uhlemann, 2000). When passed through the column, trophozoite- and schizont-
infected erythrocytes were retained in the column, whereas uninfected erythrocytes and ring-
stage infected erythrocytes flowed through. The detailed protocol as previously described 
(Vogt, 2008). In brief, the MACS was fixed to an adapter and mounted to the magnetic field 
following the manufacturer’s instruction. Prior to passing through the column, the matrix was 
equilibrated with MACS buffer. The stopcock of the column was adjusted to allow a slow 
speed of flow through of the culture (1 drop per second) so as to retain trophozoite- and 
schizont-infected erythrocytes efficiently. Afterwards, while still applying the magnetic field, 
the column was washed with MACS buffer until the effluent was colorless. For elution the 
column was released from the magnetic field, and MACS buffer was applied to elute the 
trophozoite- and schizont-infected erythrocytes untill the effluent was colorless. The eluted 
was then put on ice and centrifuged at 3800rpm for 5 minutes, 4ºC, followed by two times 
wash with ice-cold PBS with the same centrifugation condition.  
2.2.2 Microbiological methods 
2.2.2.1 Preparation for chemo-competent E. coli 
Bacteria that can uptake exogenous DNA molecules like plasmid are so called “ 
competent cells” Chemically competent cells were prepared with a method of using DMSO 
(Inoue et al., 1990). Briefly, E. coli XL1 blue cells were inoculated on an LB Agar plate and 
grown overnight at 37°C. On the next day, a single colony was inoculated in 5 ml of SOB 
medium and grown overnight at 37°C, on a shaker at 230 rpm. 5 ml of starting culture was 
again inoculated in 250 ml of SOB medium, grown in a sterile 2-liter flask at 37°C on a 
shaker at 230 rpm till an O.D. 600 of 0.6 was reached. The culture was then rapidly cooled 
down on ice for 10 minutes and subsequently centrifuged at 6000 rpm, 4°C for 15 minutes. 
The supernatant was discarded, and pelleted cells were resuspended in 20 ml of ice-cold TB 
buffer, followed by addition of 1.4 ml of DMSO with gentle stirring. Cells were cooled on ice 
for another 10 minutes and then aliquoted (100 µl) in Eppendorf tubes bathed in ethanol/dry 
ice slurry before storage at -80 °C. 
2.2.2.2 Transformation of competent E. coli cells 
Transformation of competent cells is defined as the process of insertion of exogenous 
DNA material into competent cells via a short heat shock (Inoue et al., 1990). Briefly, 50 µl 
of chemo-competent E. coli cells were thawed on ice, to which 5 µl of plasmid was added and 
mixed gently. The mixture was incubated on ice for 30 minutes, subsequently heat-shocked in 
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a water bath at 42°C for 45 seconds, and then immediately placed on ice for 2 minutes. 
Afterwards, 1000 µl of SOC medium pre-warmed at 37 °C, was added and the mixture 
incubated at 37 °C for 1 hour, while on a shaker at 230 rpm. 100 µl of this transformed cell 
suspension was plated on LB Agar plates containing 100 µg/ml Ampicillin or 30 µg/ml 
Kanamycin, and incubated overnight at 37 °C. The rest 900 µl of culture was centrifuged at 
6000 rpm for 1 minute, and the pellet was plated on LB agar in a similar manner. The plates 
were checked after 16 to 20 hours for growth of bacterial colonies, where each colony 
represented growth from a single clone.  
2.2.2.3 Isolation of plasmid DNA from bacteria-- Miniprep 
A single colony was inoculated into 10 ml of LB medium (supplemented with 
antibiotics) and grown overnight at 37°C with shaking at 230 rpm. Plasmid DNA was isolated 
from the E. coli using High Pure Plasmid isolation Kit (Roche, Mannheim). This system is 
based on alkaline lysis of cells followed by adsorption of DNA onto a special matrix. DNA 
was eluted using TE buffer and stored at -20°C.  
2.2.3 Molecular biology methods 
2.2.3.1 DNA isolation from P. falciparum 
To isolate P. falciparum from the erythrocytes, 2 ml of resuspended culture (at least 
5% parasitemia, 50% trophozoite) were transferred into a 15 ml falcon tube and centrifuged at 
1900 rpm for 3 minutes. The pellet was resuspended with 2 ml of 0.1% Saponin in PBS, 
inverted several times and incubated at room temperature for 3 minutes. The lysate was 
centrifuged at 4000 rpm for 5 minutes, and the supernatant was discarded. The pellet was 
washed with 2 ml of PBS and centrifuged in the same setting. The pellet was resuspended in 
200 µl of PBS (pH7.2) and transferred to an Eppendorf tube.  
The isolation of genomic DNA was carried out via DNeasy kit (Qiagen). Briefly, the 
parasite was lysed with 200 µl of AL buffer with 20 µl of proteinase K, and incubated at 70°C 
for 10 minutes. 200 µl of ethanol was added and the mixture vortexed. The mixture was then 
transferred to a Mini spin column, and centrifuged at 8000 rpm for 1 minute. The flow-
through was discarded and 500 µl of AW1 was added, followed by centrifuge at 8000 rpm for 
1 minute. Again, the flow-through was discarded and 500 µl of AW2 was added, followed by 
centrifugation at 14,000 rpm for 3 minutes. The column was then transferred to a new 
Eppendorf tube, and 100 µl of AE buffer was loaded onto the membrane, incubated for 1 
minute at room temperature and centrifuged at 8000 rpm for 1 minute. An additional 100 µl 
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of AE buffer was loaded onto the membrane, incubated for 1 minute at room temperature and 
centrifuged at 8000 rpm for 1 minute. The genomic DNA was stored at -20°C. 
2.2.3.2 RNA isolation from P. falciparum parasites 
To isolate the trophozoite-stage parasites from erythrocytes, two 25 cm plates of 
culture were prepared. After removing 25 ml of medium, the cells were resuspended cells 
with residual medium. The culture was then transferred to a 50 ml falcon tube, filled up with 
sterile PBS and centrifuged at 2000 rpm for 2 minutes without brake at 800 rpm. The 
supernatant was discarded and the pellet was washed with sterile PBS and centrifuged again 
with the same speed. The supernatant was discarded and the tube was filled with PBS till 25 
ml. then the volume was made up to 50 ml with freshly prepared 0.2% Saponin. The tube was 
inversed several times until the liquid became translucent, which was followed by 
centrifugation at 3800 rpm, 4°C for 8 minutes. The supernatant was discarded. 
To extract RNA from the parasites, 1 ml of Trizol® was added to the pellet and mixed 
gently, followed by incubation at room temperature for 10 minutes. 200µl of chloroform was 
added and the mixture was shaken vigorously by hand for 15 seconds. The mixture was 
chilled on ice for 3 min and then centrifuged at 12, 000 x g for 15 minutes at 4°C. The upper, 
aqueous, phase contained mostly RNA and was transferred to a new Eppendorf tube carefully. 
500 µl of ice-cold isopropanol was then added to the new tube, incubated at room temperature 
for 10 minutes and centrifuged at 12, 000 x g for 10 minutes at 4°C.  The pellet was washed 
twice with 75% ethanol and centrifuged at 7500 x g for 5 minutes at 4°C. The RNA pellet was 
dried at room temperature to eliminate any contaminating ethanol remained. The RNA pellet 
was dissolved in a certain amount of Ribonuclease-free water (treated with 
diethylpyrocarbonate) depending on the size of the RNA pellet, in the range of 20 to 100 µl. 
The RNA was stored at -80°C. 
2.2.3.3 Reverse Transcription 
The cDNA was synthesized with SuperScript® III First-Strand Synthesis  (Invitrogen, 
USA). In brief, 1µg of isolated RNA was mixed with oligo(dT)20 and dNTP for denaturing at 
65°C for 5 minutes. The mixture was then put on ice for 2 minutes. 10 µl of cDNA synthesis 
Mix (containing enzymes and buffer) was then added to the RNA mixture, incubated at 50°C 
for 50 minutes to synthesize cDNA. The reaction was heat-inactivated at 85°C for 5 minutes. 
The RNA was then removed by RNase H at 37°C for 20 minutes. The cDNA was then stored 
at -20°C freezer. 
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2.2.3.4 Polymerase Chain Reaction (PCR) 
Specific DNA sequences can be amplified in vitro using PCR, that involves a 
temperature dependent DNA polymerase, a template DNA sequence and forward and reverse 
primers that bind specifically to the DNA template (Saiki et al., 1985). In this study, PCR 
amplification of pfcrt, pfmdr1 and the genes located within the B5M12 locus was used to 
identify polymorphisms within the lab strains and field isolates.  
Phusion Polymerase possesses proofreading activity, which is required for DNA 
sequencing and detection of polymorphisms. Due to the high AT-rich and repetitive sequence 
of P. falciparum and numerous polymorphisms in different strains, the primers for sequencing 
often failed to anneal to the DNA template or showed unspecific binding. All the primers 
ordered were optimized with gradient annealing temperatures ranging from 58°C~62°C. 
Furthermore, the length of annealing and elongation also varies, depending on the length of 
the products. The PCR mix and the PCR cycling conditions are listed as follow: 
PCR for sequencing    Cycling conditions 
ddH2O     36  µl  Initial denaturation :  98°C, 4 min 
5 x Phusion HF Buffer   10  µl  Denaturation :  98°C, 45 sec 
10mM dNTP mix    2    µl  Annealing :  Optimized °C, 45~60 sec 
Forward primer (50nM)   0.5 µl  Extension :  72°C  45~120 sec 
Reverse primer (50nM)   0.5  µl Final extension : 72°C, 10 min 
Template      0.5  µl Termination :  4°C 
Phusion Polymerase    0.5  µl Cycles :  35~40 
Total Volume   50.0  µl 
When PCR is performed to detect length polymorphism, proofreading activity is not 
required. Therefore, I used Euro Taq DNA polymerase. The PCR mix and PCR cycling 
condition were described as follows: 
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PCR for length polymorphism  Cycling conditions 
ddH2O           16.75  µl  Initial denaturation :  94°C, 4 min 
10 x Euro Taq Buffer      2.5 µl  Denaturation :  94°C, 45 sec 
50mM MgCl2   1.25 µl  Annealing :  Optimized °C, 45~60 sec 
10mM dNTP mix   2.5  µl  Extension :  68°C  45~120 sec 
Forward primer (50nM)   0.5 µl  Final extension : 68°C, 10 min 
Reverse primer (50nM)   0.5 µl  Termination :  4°C 
Template      0.5 µl  Cycles :  35~40 
Euro Taq DNA polymerase   0.5 µl   
Total Volume   25.0 µl 
For pyrosequencing, the amount of concentration was reduced because excess of 
primer (biotinylated) could interfere with the isolation of the PCR product for 
pyrosequencing. 
PCR for pyrosequencing   Cycling conditions 
ddH2O           16.75  µl  Initial denaturation :  94°C, 4 min 
10 x Euro Taq Buffer         5 µl  Denaturation :  94°C, 45 sec 
50mM MgCl2     2.5 µl  Annealing :  Optimized °C, 45~60 sec 
10mM dNTP mix      5  µl  Extension :  68°C  45~120 sec 
Forward primer (10nM)   0.5 µl  Final extension : 68°C, 10 min 
Reverse primer (10nM)   0.5 µl  Termination :  4°C 
Template         2 µl  Cycles :  35 
Euro Taq DNA polymerase   0.5 µl   
Total Volume   50.0 µl 
 
2.2.3.5 Agarose gel electrophoresis of nucleic acids 
Agarose is widely used in separation of DNA or RNA molecules according to their 
size and charge. The resolution of the nucleic acid bands is dependent on the concentration of 
the agarose gel. The most common concentration used for DNA electrophoresis is from 0.7 % 
(for large 5–10kb DNA fragments) to 2% (for small 0.2–1kb fragments). For higher 
resolution, in this study, I use 3% metaphor agarose gels, which is commonly used for 20 bp 
to 800 bp nucleotides separation.  
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For DNA electrophoresis, an appropriate amount of agarose was weighted and mixed 
with TAE buffer, and boiled in a microwave until the agarose completely dissolved. The gel 
was then cooled down to 55°C, 1:10000 amount of EtBR was added and poured in a gel 
mould. 6 x DNA loading buffer was added to the DNA samples for a final concentration of 
1X and samples were then loaded onto the gel. A 1 kb Plus DNA Ladder™ was run alongside 
the samples as a size marker. Electrophoresis was carried out for 30 to 240 minutes at a 
constant voltage of 70~140 V for various gels as needed. Samples were photographed under 
UV illumination using a DC120 Zoom Digital camera (Kodak). 
RNA has a tendancy to  form secondary structure due to its single strand nature. Thus, 
for RNA electrophoresis, I utilized formaldehyde to maintain the denatured form of RNA. 
The gel was prepared as follow: 
Agarose     0.28 g 
ddH2O    30 ml 
20 x RNA gel  running buffer    2 ml 
The mixture was boiled in microwave until the agarose gel dissolved completely, after 
which it allowed to cool to 55°C. Then 0.5 µl of EtBR was added and the molted gel was 
poured into gel mold. After gel solidification, 8 ml of 37% formaldehyde was added onto the 
surface of the gel under a chemical hood, kept for 1 minute and removed. Electrophoresis was 
carried out for 60 minutes at a constant voltage of 60 V in RNA gel running buffer. The gel 
was then photographed under UV illumination using a DC120 Zoom Digital camera (Kodak). 
2.2.3.6 Agarose gel extraction and PCR product purification 
In order to purify specific DNA fragments from the agarose gel or clean up the PCR 
product from the PCR mixture, I utilized the QIAGEN gel extraction kit. In brief, the cut 
agarose gel was solubilized at 55°C till it completely dissolved. In the presence of isopropanol 
and high salt concentration, the DNA was separated and bound to a QIAquick™ membrane 
inside the column, while the contaminants flowed through. After one wash with 75% Ethanol, 
the DNA was eluted with an appropriate amount of TE buffer or sterile water. For PCR 
product purification, the product mixture was applied onto the column without the first step of 
solubilizing under 55°C. The purified fragments were stored at -20°C.  
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2.2.3.7 Restriction digestion of DNA 
DNA can be enzymatically cleaved by restriction endonucleases, which recognize 
short, often palindromic sequences and catalyse a break in the backbone of DNA by 
hydrolysis. Cleavage by various restriction enzyme results in two types of end: either blunt or 
sticky. Sticky end refers to a few nucleotide overhang after cleavage, whereas no such 
overhang is found in blunt end. In this study, I used restriction enzymes to identify the pfcrt 
(ApoI) and pfmdr1 RFLPs from field isolates by digestion of amplified PCR fragments 
containing polymorphic nucleotides. The restriction digestion mix and reaction condition is 
described as follow:  
 
  Restriction Digestion Mix     
ddH2O           11.5  µl  
DNA materiel    4  µl  
10 x Buffer    2  µl  
10 x BSA    2  µl  
Enzyme  0.5 µl  
Total Volume  20  µl  
 
Incubated for 60 minutes at 37°C  
Or for 6 hours at 50°C (ApoI). 
 
 
2.2.3.8 DNA sequencing 
DNA samples were sent to GATC, (Konstanz) for sequencing. The Sanger 
dideoxynucleotide method (Sanger et al., 1977) was used. BioEdit software was used to 
analyze the sequences obtained. 
2.2.3.9 Pyrosequencing 
Pyrosequencing was used to detect pfcrt polymorphism at position 326. The PCR 
reaction used was as described in 2.2.3.4. 20 µl of the PCR product was used for each 
pyrosequencing reaction. The PCR products were pipetted into 96 well plates, and purified 
using Streptavidin Sepaharose beads (GE Healthcare) following which by co-denaturation of 
the biotinylated PCR product with the sequencing primer (15 pmol/reaction) was performed 
using the PyroMark Q96 Vacuum Prep Workstation (Qiagen), according to the 
manufacturer’s protocol. Pyrosequencing was then performed using PyroMark Gold Q96 
Figure 2.1 Schematic view of the nested system used 
for the detection of the polymorphism in the pfmdr1 
gene of P. falciparum (Duraisingh et al, 2000). 
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reagents (Qiagen) on the PyroMark™Q96 ID system (Qiagen), according to the 
manufacturer’s protocol.  
2.2.4 Biochemical and cell biology methods 
2.2.4.1 SDS-PAGE electrophoresis 
SDS is an anionic detergent, which is capable of denaturing the secondary and non-
disulphide linked tertiary structure of the protein while adding a negative charge. Denatured 
proteins can be separated by Polyacrylamide gel electrophoresis (PAGE) according to their 
charge to mass ratio of each protein. Protein samples were heated in the presence of β-
mercaptoethanol to reduce disulphide bonds. PAGE gels are formed by polymerization of 
Acrylamide and N,N’-methylbisacrylamide. The polymerization is initiated by 
ammoniumpersulfate (APS) and catalysed by tetramethylethylenediamide (TEMED). The 
concentration of Acrylamide can alter the separation of proteins on the gel, i.e. higher 
concentration of acrylamide can be used to separate lower molecular weight proteins, and vice 
versa. The gel consists of two parts – a stacking gel and a resolving gel. Stacking gel contains 
the loading wells and has larger pores, allowing the protein sample to concentrate and 
compress in front of the resolving gel, which has smaller pores that separate the protein 
samples (Laemmli, 1970). Composition of each gel was as described: 
 
Stacking Gel:      Resolving Gel:  
Component Volume  Component 8% 10% 12% 
       
ddH20 3.46 ml  ddH20 4.68 ml 3.96 ml 3.35 ml 
1M Tris pH6.8 630µl  1M Tris pH6.8 2.50 ml 2.50 ml 2.50 ml 
10% SDS 50 µl  10% SDS 100 µl 100 µl 100 µl 
30% Acrylamide 830 µl  30% Acrylamide 2.66 ml 3.33 ml 4.00 ml 
10% APS (fresh) 50 µl  10% APS (fresh) 100 µl 100 µl 100 µl 
TEMED 5 µl  TEMED 6 µl 6 µl 6 µl 
Total volume 5.025 ml  Total volume 10 ml 10 ml 10 ml 
 
Before loading, the protein samples were diluted 1:1 (v/v) with 2 x SDS loading buffer 
and heated at 70°C for 5 minutes, and centrifuged briefly. 5 µl of a protein ladder was loaded 
alongside the samples. Electrophoresis was carried out at 60 mA constant current for 30~45 
minutes in SDS gel running buffer until the bromophenol blue dye in the samples ran to the 
bottom of the gel.  
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2.2.4.2 Coomassie staining for proteins 
Coomassie Brilliant Blue is an anionic dye, which binds the proteins non-specifically. 
Thus, after electrophoresis, Coomassie Brilliant Blue stained proteins samples immobilized 
on the SDS-PAGE gel. Coomassie staining was used to detect protein induction in E. coli 
cells. SDS-PAGE gels were quickly washed with deionised water after electrophoresis and 
then stained with Coomassie staining solutions for 5 minutes at room temperature with 
shaking. After staining, the gel was destained in the destain buffer with shaking until the 
bands were detectable. 
2.2.4.3 Western blotting 
Western blotting is a method to detect specific protein after SDS-PAGE. By 
transferring the gel onto a membrane, normally Polyvinyldifluoride (PVDF) or Nitrocellulose. 
The membrane is subsequently probed with antibodies against proteins of interest.   
While running the SDS-PAGE, one piece of the PVDF membrane and 6 pieces of 
Whatman filter paper were cut to the size of gel.  The PVDF membrane was activated by 
soaking it in methanol for 30 seconds. PVDF and Whatman filter papers were kept in transfer 
buffer for at least 5 minutes. 3 pieces of filter paper were laid on the electrode of transfer 
chamber, and then PVDF was laid above the filter papers. The SDS-PAGE gel was rinsed 
with sterile water 2 to 3 times and transferred carefully onto the PVDF membrane. Then, 
another 3 pieces of filter paper was placed on the gel. The excessive transfer buffer and air 
bubbles in between the gel, membrane and the filter papers was removed by rolling and 
pressing with a falcon tube. Transfer was carried out at a constant current 15V, 230 mA for 60 
to 90 minutes according to the size of the target protein. 
After the transfer, the membrane were incubated overnight with the blocking solution 
and subsequently incubated with a 1:1000 dilution of primary antibody prepared in 1% BSA 
in PBS. The membrane was then washed with PBST, 3 times for 10 min each, after which the 
membrane was incubated with secondary antibody coupled with 2nd antibody diluted 1:10000 
in blocking solution at room temperature for 20 min, followed by washing 3 times for 10 
minutes with PBST and one time with PBS for another 10 minutes. The membrane was 
developed with the Enhanced Chemiluminescence kits (ECL). Peroxidase substrate from the 
kit was applied to the membrane for one minute at room temperature and then drained. 
Peroxidase conjugated 2nd antibody attached on the membrane acts on the substrate, resulting 
in emission of luminescence, which was used to expose an X-Ray film in a dark room. X-Ray 
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films were developed using a Hyperprocessor developing machine (Amersham Pharmacia 
Biotech).  
2.2.4.4 Protein induction and extraction from E. coli 
Recombinant protein for antibody generation was produced in E. coli BL21 (DE3) 
strain. The HECT domain of ubiquitin transferase was constructed and fused with a C-
terminal 6 x His-tag and expressed under T7 promoter in PET 28a (+) plasmid. Isopropyl-ß-
D-thiogalactopyranoside (IPTG), which binds to lac repressor and inactivates the repressor, 
was used to induce protein expression. 
A single colony containing the gene of interest was inoculated in 10 ml of LB medium 
with antibiotics, grown overnight at 37°C with shaking at 230 rpm. The culture was then 
inoculated in 3 liters of LB medium in the presence of antibiotics, grown at 37°C on a shaker 
at 230 rpm until an O.D. 600 of 0.4~0.6 was reached. IPTG was added to make a final 
concentration of 0.4 mM. In our case, the solubility or amount of protein expressed at 37°C 
was not ideal. I therefore optimized the condition of protein expression. The induction with 
0.4 mM IPTG was then carried out at 18°C overnight with shaking at 135 rpm. The culture 
was then centrifuged at 5000 rpm, 4°C for 5 minutes, and the supernatant discarded. Due to 
the insolubility of the protein, the pellet was resuspended in 10 ml of lysis buffer and vortexed 
vigorously for 1 hour at room temperature. The lysate was then centrifuged at 12000 rpm, 4°C 
for 1 hour. The supernatant was subsequently used for protein purification; while the pellet 
was kept in loading buffer as control. 
2.2.4.5 His-tag protein purification and concentration 
Ni-NTA (nickel-nitrilotriacetic acid) agarose beads were used for affinity-purification 
of 6 x His-tagged proteins. 0.5 ml of the 50% Ni-NTA slurry  (Invitrogen) was added to a 
column, and the flow-through was discarded. The matrix was then equilibrated with 5 ml of 
lysis buffer. The supernatant from the protein extraction was loaded onto the column, and the 
flow-through was collected (unbound). The column was then washed twice with 10 ml of 
Wash buffer I and collect the flow-through (wash I, II) collected. Again, the column was 
washed twice with 10 ml of Wash buffer II and the flow-through (wash III, IV) collected. The 
protein was then eluted with 5 times with 0.5 ml of elution buffer. The whole purification was 
carried out at 4°C in the cold room.  
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2.2.4.6 Protein precipitation with Trichloroacetate (TCA) 
Proteins samples containing Guanidine HCl will form a precipitate in the presence of 
SDS. Thus, TCA precipitation can be applied to remove Guanidine HCl. The samples were 
diluted to 100 µl and mixed with equal volumes of 10% TCA. Samples were kept on ice for 
20 minutes and centrifuged at 13,000 rpm, 4°C for 15 minutes. The pellet was washed with 
100 µl of ice-cold ethanol, dried, and resuspended in loading buffer. 
2.2.4.7 Detection of protein concentration with Bradford 
The Bradford assay is based on a dye binding reaction in which a differential color 
change of the dye occurs in response to the protein concentration. When binding to a protein, 
the absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 dye shifts 
from 465 nm to 595 nm. The dye binds to primarily basic and aromatic residues, especially 
arginine. However, interferences may be caused by chemical-protein and/or chemical-dye 
interactions. For standard protocol, the dye reagent was diluted 5 times with sterile water. The 
linear range of BSA standard solutions from 1ng/ml to 1 mg/ml (5 concentrations) was 
prepared. 1 ml of diluted was mixed with 1 µl of standard or sample, vortexed and incubated 
at room temperature for 5 minutes. The measurements of absorbance at 595 nm were carried 
out with duplicated samples and BSA standards.  
2.2.4.8 Concentration of protein samples 
The concentration of proteins samples for antibody generation was required to be 
above 30 ng/µl. Thus, samples under this concentration was loaded to Amicon Ultra 
Centrifugal Filter Devices (Millipore) and centrifuged at no more than 4000 rpm, 4°C till the 
residue volume was around 150 to 200 µl. 
2.2.4.9  P. falciparum protein extraction 
To obtain crude protein extracts for Western blot analysis, MACS-purified infected 
erythrocytes were broken via a hypo-osmotic shock. This method will remove hemoglobin, 
the most abundant protein in the erythrocytes. Two big plates of parasite culture (at least 5 % 
parasitemia, trophozoite stage) were resuspended and centrifuged at 1900 rpm for 2 minutes. 
The pellet was washed in 14 ml of PBS and centrifuged in the same condition. The pellet was 
resuspended in 0.5 ml of PBS and lysed in 10 ml of Erythrocyte lysis buffer, and shook 
vigorously and incubated on ice for 3 minutes. Repeat this step if the lysis appears 
incomplete. The tube was then centrifuged at 10,000 rpm, 4°C for 10 minutes. The pellet was 
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washed with 10 ml of ice-cold PBS and centrifuged as above. The pellet was then ready for 
SDS-PAGE and Western blot analysis. 
2.2.4.10 Immunofluorescence assay (IFA) 
In preparation for IFA, young trophozoite stage infected erythrocytes were purified 
using the MACS column. Infected erythrocytes were then fixed for 30 minutes with 4% 
formaldehyde + 0.0075% glutaraldehyde in PBS at room temperature. Cells were washed 3 
times with PBS and centrifuged at 2000 rpm for 1 minute. The cells were then permeabilized 
with 0.1% TritonX-100 in PBS for 15 minutes and washed 3 times as above. After washing, 
the cells were incubated in 10 mM NH4Cl for 10 minutes, followed by another 3 washes. The 
cells were then blocked in 3% BSA in PBS for 3 hours at room temperature. The 1st antibody 
was then added to the cells with at 1:250 or 1:500 dilutions and incubated for 2 hours at room 
temperature. Then, cells were washed 3 times as above, followed by incubation with 2nd 
antibody conjugated with Alexa fluorophore along with 5 µM of Hochest 33342 for 30 
minutes at room temperature in the dark. After staining, the cells were subsequently diluted in 
PBS and transferred to a perfusion chamber and allowed to adhere to poly-L-lysine cover 
slips. Cells were observed on a LSM 510 laser-scanning confocal microscope (Zeiss, Jena) 
equipped with an objective providing 63-fold magnification (C-Apochromatic x63/1.2 H2O 
immersion). Hochest was excited at 364 nm and emission detected using a 385-470 filter, 
whereas 2nd antibody conjugated with Alexa 488 was excited using the 488 nm Argon laser 
and the emission was captured through a 505~550 filter.  
2.2.4.11 Antibody generation 
To generate antibody against ubiquitin transferase, 50 µg of protein samples was 
mixed with the same volume of complete Freund adjuvant (Invitrogen), mixed well and 
injected subcutaneously into the mouse. After three weeks and another two weeks later, the 
same amount of protein was mixed with incomplete Freund adjuvant (Invitrogen) and injected 
subcutaneously into the mouse. Ten days after the last immunization, the mouse was 
sacrificed. The blood was collected and kept at room temperature for 30 minutes to aggregate 
the blood cells and platelets. The aggregate was then removed and the plasma was centrifuged 
at 13,000 rpm, 4°C for 15 minutes. The polyclonal antibody (supernatant) was transferred to a 
new sterile Eppendorf tube and stored at -80°C. In total, 4 mice were used for antibody 
generation. 
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2.2.5 Mathematical methods 
2.2.5.1 Correlation and linkage 
In this project, the correlation study was performed using an Excel sheet calculation 
designed by Prof. W. Stein from the Department of Biological Chemistry, Hebrew University 
of Jerusalem, Israel. The calculation was performed based on the simple regression method as 
described by Haley and Knott (Haley and Knott, 1992). The polymorphisms were arranged as 
rows in the table. For each of the 50 field isolates and lab strains, arranged in columns, the 
appropriate quinine IC50-values or pfcrt 76 position polymorphisms were inserted. When the 
haplotype of a polymorphism was the same as Dd2 strain, a 1 was entered into the table at the 
appropriate intersection, whereas if the haplotype was the same as the HB3 strain, a 0 was 
input. This then gave a matrix 0 and 1. For each polymorphism (each row), a Pearson 
regression of the 0’s and 1’s was performed against the measured accumulation or the quinine 
IC50-value, to yield the Pearson r for the polymorphism. (The Pearson regression for a 
polymorphism is a measure of how well the pattern of 0 and 1 values across the strains, for 
that polymorphism, correlated with the measured values of quinine IC50-values or the 
polymorphism of 76 position of PfCRT). The probability p was determined with the 
appropriate degrees of freedom. For all the polymorphisms, the p value was divided by the 
mean of p values. This ratio showed whether the p value was higher or lower than the mean. 
The logarithm of this ratio gave the LOD (logarithmic of odd) score. Therefore, when a 
marker had a negative LOD score, its p value was higher than the mean, and vice versa. A p 
value 100 times less than the mean (p<0.01) was taken as the significance threshold and a line 
at this level was drawn in the LOD score figures. The sign of the regression coefficients used 
to derive the LOD scores indicated whether or not an increase or a decrease of the quinine 
IC50-value was being reported. When a polymorphism had a negative Pearson regression 
value, it had a decreasing effect on the quinine susceptibility or association with PfCRT K76T 
mutation, and vice versa. The figures were drawn in SigmaPlot 11.0. 
2.2.5.2 Grouping  
The values of the drug susceptibility assay in field isolates and lab strains were 
grouped according to different haplotype combinations. A Student T-test or One-way 
ANOVA test was performed to test the statistical significance between each group. 
Alternatively, for groups with few numbers of strains, I used Fisher's Least Significant 
Difference (LSD) test for calculation. All the grouping figures were drawn in SigmaPlot 11.0. 
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3 Results 
3.1 Identification of novel microsatellite markers and re-
definition of the B5M12 locus 
The previously identified B5M12 locus is approximately 185 kbp in length and is 
flanked by BM25 and PE14D microsatellites. However, it was a challenge to identify 
candidate genes in such a large region. To search for other crossing-over events within the 
B5M12 locus in the F1 progeny of Dd2 x HB3 crosses and to narrow down the precise 
location of the B5M12 locus, a former PhD student and I identified several new microsatellite 
markers within this locus, calculating the LOD score for each maker. The microsatellite 
markers are listed in Table 2.3. From 16 microsatellite markers, the upstream SM15 and 
SM17 markers and the downstream SM22 marker had significantly lower LOD scores (4.85, 
4.85, and 5.93, respectively) compared with the scores (6.55) of the other microsatellite 
markers in the B5M12 locus. We were thus able to eliminate many candidate genes within the 
B5M12 locus. 
3.2 Identification of polymorphisms in the B5M12 locus 
The redefined B5M12 locus is a fragment of approximately 158 kbp in length on 
chromosome 7. It is flanked by the SM15 (246 kbp) and SM22 (403 kbp) microsatellite 
markers. The B5M12 locus is approximately 43 kbp away from the pfcrt locus (Fig. 3.1). The 
data collected from the PlasmoDB website (released 2011, October) indicated that there are 
33 genes within the B5M12 locus, including 16 annotated genes, 13 genes with unknown 
function, and 4 tRNAs (Table 3.1). The sequence tagged site (STS) listed in the first column 
of Table 3.1 indicate the microsatellite markers I used in this study. All of the information 
regarding the STS were collected from the NCBI (National Center for Biotechnology 
Information) website and from the novel microsatellite markers we identified (Table 2.3). 
Other data, such as genomic locations, annotated functions, protein lengths (a.a.), and 
functional domains, were collected from the PlasmoDB and GeneDB websites. 
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To identify polymorphisms between the parental strains HB3 and Dd2, I first used the 
NCBI BLAST tool (or “blasted”) to compare the genomic sequences of each gene in the 3D7 
strain in BroadMIT against the Dd2 and HB3 genomes. I subsequently aligned the genomic 
sequences from the 3D7, Dd2, and HB3 strains using the BioEdit software (Version 7.0.9.0, 
2007) to identify possible codon and length polymorphisms within the B5M12 locus. From 
the alignment results, I identified seven genes (PF07_0017, MAL7P1.20, PF07_0023, 
MAL7P1.202, MAL7P1.203a, MAL7P1.320, and MAL7P1.206) that contained no 
polymorphisms between the Dd2 and HB3 strains. For certain genes within the locus, 
polymorphisms could not be identified, or the publically available sequence information was 
incomplete. I decided to re-examine all of the codon and length polymorphisms by 
sequencing the missing or incomplete portions of the coding genes within the B5M12 locus.  
 
 
Figure 3.1 Schematic representation of the B5M12 and pfcrt loci on chromosome 7, 
including relevant microsatellite markers, genes, and chromosomal positions (in Mbp).  
 
 
The primers (see Materials and Methods, Table 2.2) were designed within the regions 
that were conserved between Dd2 and HB3 and were blasted against the Plasmodium 
falciparum genome using the NCBI primer tool to verify the primer specificity. The PCR 
conditions were determined by testing the various primers using a gradient of annealing 
temperatures from 58°C to 62°C. The target fragments were amplified by the majority of the 
primers. However, for some highly AT-rich genes, the PCRs were performed at lower 
annealing temperatures, from 45°C to 55°C. The PCR products were then sent for sequencing 
to GATC biotech, Konstanz, Germany. The sequencing results from Dd2 and HB3 were 
subsequently analysed by sequence alignment with 3D7 strain sequences. However, four 
genes (MAL7P1.300, MAL7P1.339, MAL7P1.340, and MAL7P1.203b) could not be 
amplified by PCR, despite the use of different primer sets (data not shown). In total, I 
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identified 18 polymorphic genes. All of the identified mutations and length polymorphisms 
are listed in (Table 3.1). I identified 82 codon polymorphisms and 34 length polymorphisms 
in 18 polymorphic genes within the B5M12 locus. To facilitate further linkage studies, I also 
examined the genes flanking the B5M12 locus, including two upstream genes (MAL7P1.17 
and PF07_0015) and three downstream genes (PF07_0025, PF07_0026, and PF07_0029). I 
identified 13 codon polymorphisms and 7 length polymorphisms in these flanking genes. I 
selected 80 polymorphisms in 12 genes within the B5M12 locus for further correlational 
studies in a total of 50 field isolates and lab strains. 
 
 
